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What is already known about this topic? 
• Topical photodynamic therapy (PDT) is one of a range of established treatment 
options for low-risk basal cell carcinoma (BCC). 
• BCC clearance is reported to be higher with imiquimod than with single-cycle PDT 
What does this study add? 
• This is the largest systematic review and meta-analysis to-date of PDT for BCC and 
incorporates NICE-approved GRADE assessment of evidence quality including 15 
RCTs (2,327 patients with 3,509 BCCs). 
• Serious adverse reactions are less common with PDT than imiquimod. 
• Peak pain is higher with PDT than topical therapies but is of shorter duration. 
• Fractionated PDT offers superior clearance to conventional PDT. 
• Combination PDT treatments show promise but require further study. 
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Abstract 
Background: Topical photodynamic therapy (PDT) is an established treatment option for 
low-risk basal cell carcinoma (BCC). 
Objectives: Compare efficacy, cosmesis and tolerability of PDT for BCC with alternative 
treatments. 
Methods: MEDLINE/PubMed/EMBASE/CENTRAL databases were searched from inception 
until 1 September 2017. Included studies were randomised controlled trials (RCTs) of PDT 
for nodular (n) and superficial (s) BCC reporting at least one of the outcomes: clearance at 3 
months, and sustained at 1  or 5 years; recurrence at ≥1 year; cosmesis; adverse events; 
tolerability.  
Results: From 2,331 search results, 15 RCTs (2,327 patients; 3,509 BCCs) were included.  PDT 
efficacy (5-year sustained clearance) was high although inferior to excisional surgery (nBCC 
pooled RR 0.76; 95% CI 0.63–0.91), and without re-treatment of partially-responding 
lesions, was modestly inferior to imiquimod (sBCC: RR 0.81; 95% CI 0.70-0.95) and similar to 
fluorouracil (sBCC: RR 0.88; 95% CI 0.75-1.04). Five-year sustained clearance was inferior 
with conventional versus fractionated PDT (sBCC: RR 0.76; 95% CI 0.68-0.84). PDT cosmesis 
was superior to surgery (sBCC: RR 1.68; 95% CI 1.32-2.14; nBCC: RR 1.82; 95% CI 1.19-2.80) 
and cryosurgery (BCC: RR 3.73; 95% CI 1.96-7.07), and without re-treatment of partially-
responding lesions was similar to imiquimod (sBCC: RR 1.01; 95%CI 0.85-1.19) and 
fluorouracil (sBCC: RR 1.04; 95% CI 0.88-1.24). Peak pain was higher but of shorter duration 
with PDT than topical treatments.  Serious adverse reactions were rarer with PDT than 
imiquimod (sBCC: RR 0.05; 95% CI 0.00-0.84) and fluorouracil (sBCC: RR 0.11; 95% CI 0.01-
2.04). Combination PDT regimens demonstrated reduced recurrence and improved 
cosmesis; however, results from these small studies were often non-significant.  
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Conclusions: PDT is an effective treatment for low-risk BCC, with excellent cosmesis and 
safety.  Imiquimod has higher efficacy than single-cycle PDT though more adverse effects. 
Highest efficacy is with excisional surgery.  Fractionated and combination PDT options 
warrant further study. 
  
Page 4 of 97British Journal of Dermatology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
5 
 
Introduction 
Basal cell carcinoma (BCC) is the commonest cancer worldwide, with reported incidence 
increasing.
1
  BCCs form a substantial and growing proportion of a dermatologist’s workload 
and are a large burden to Western health services.
2
  An effective treatment armamentarium 
is required, alongside prevention strategies.  This systematic review examines randomized 
controlled trials (RCTs) comparing conventional topical photodynamic therapy (PDT) with 
alternative treatments, including fractionated PDT and combination regimens. 
Mortality from BCC is low and BCCs almost never metastasise.  Advanced tumours, 
however, cause considerable morbidity through local tissue destruction, leading to 
disfigurement and functional compromise.
3
  The risk of morbidity depends on tumour 
location and subtype.  The majority of BCCs are low-risk, i.e. less aggressive subtypes,   
superficial BCC (sBCC) and nodular BCC (nBCC), located in anatomical areas that allow 
uncomplicated resection without substantially impairing function or cosmesis.
4
   
Surgical excision allows unparalleled cure rates but the cosmetic outcome depends 
on BCC size and location, reconstruction method, and expertise.
4-6
  One of several non-
surgical treatments available for nBCC and sBCC
7,8
 is topical PDT with 5-aminolaevulinic acid 
(ALA) or methyl aminolaevulinate (MAL).
9
 The licensed MAL-PDT protocol uses a cycle of 
two treatments, 1 week apart, with outcome reviewed at 3 months, where it is usual 
practice to re-treat partially-responding lesions.
10
 High clearance rate (although lower for 
nBCC than sBCC), excellent cosmesis and low adverse event (AE) rate are reported.
9
 
The objective of this systematic review and meta-analysis of RCTs was to evaluate 
PDT as a treatment for BCC.  Treatment choice is based not only on efficacy but tailored to 
patients’ preferences with respect to cosmesis and AE.
11,12
  This review aims to provide 
clinicians with comprehensive, up-to-date evidence regarding these outcomes from a 
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review of all available published RCTs of PDT and comparator topical, surgical and 
combination treatments for low-risk BCC.  A further purpose of this work was to inform the 
development of the updated British Association of Dermatologists and British 
Photodermatology Group guidelines for topical PDT (2018). 
 
Materials and methods 
This systematic review was performed in accordance with PRISMA guidelines
13
 and 
registered with PROSPERO International prospective register of systematic reviews 
(2017:CRD42017055804). 
Eligibility criteria 
Eligible studies are listed in Table 1.  These were published RCTs evaluating topical PDT in 
adults with BCC with one or more of the following outcomes: clearance of BCCs at 3 months, 
sustained clearance at 1 year and 5 years; recurrence rates at 1 year or more; cosmesis; 
severe pain (leading to break in treatment/use of local analgesia); other AE and treatment 
tolerability. 
Data sources and search strategy 
A systematic  search of the MEDLINE, PubMed, EMBASE and CENTRAL databases was 
conducted from inception until 1 September 2017 (see Table S1 for search terms and 
strategies).  Only studies reported in English were included.  The National Library of 
Medicine (www.clinicaltrials.gov) and European Clinical Trials Database 
(www.clinicaltrialsregister.eu) were reviewed for additional details of clinical trials.  
Reference lists of included studies were reviewed for further eligible trials. Titles and 
abstracts of studies were independently screened by three investigators and disagreements 
were resolved in consultation with a further investigator.  Full-text articles were  reviewed 
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against an a priori protocol (PROSPERO number 2017:CRD42017055804) and excluded if 
ineligible (see Table 2 for inclusion/exclusion criteria and Table S2 for details of excluded 
studies). 
Data extraction and quality assessment 
Data were independently extracted by two investigators using a standard form to record 
study details (country and setting, randomisation unit, study duration, follow-up duration 
and funding source); population details (patient characteristics, inclusion criteria, exclusion 
criteria, stratified or subgroup analyses); intervention details (outcome measure, treatment 
regimen) and results (numbers of patients randomised, analysed, with missing data, and 
with outcome).  Differences were resolved by consensus. Methodological quality of each 
study was assessed using the Cochrane Risk of Bias tool (see Table S3) and quality of 
evidence for each outcome was assessed by the GRADE criteria (see Table S4).
14
 
Data analysis 
Extracted outcomes were combined for the meta-analysis, where possible, using Review 
Manager (RevMan 5.3.5) and analysed on an intention-to-treat (ITT) basis, using patient 
data if available and lesion data otherwise. Inconsistency and heterogeneity between 
studies was assessed using the I
2
 test and the Chi-squared tests where p < 0.05 was 
considered statistically significant. 
 
Results 
Study selection 
The 2,331 results from the systematic search gave 155 articles for full-text assessment 
resulting in 15 eligible RCTs published between 2001-2017 (Figure 1) involving 2,327 
patients and 3,509 BCCs.  Most study populations were white, middle-aged and elderly 
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patients with all but one trial occurring in North America, Europe or Australia.  The follow-
up ranged from 3 months to >5 years.  Treatment protocols for the included studies are 
summarised in Table 3. 
PDT vs. Placebo cream-PDT 
Two RCTs, involving 150 primary nBCC, were reported together.
15
  A cycle of two 
treatments, 1 week apart was performed; at 3 months, partially-responding lesions were re-
treated with a second cycle.  All lesions were excised and examined histologically. 
MAL-PDT showed superior clearance at 3 months post-final treatment compared with 
placebo-PDT (risk ratio (RR) 2.75; 95% confidence interval (CI) 1.84–4.10, Table 4) and better 
cosmesis (RR 3.00; 95% CI 1.80–5.01; Table 5), while manageable pain was worse (RR 1.37; 
95% CI 1.14–1.66; Table 6). 
PDT vs. Cryosurgery 
Two RCTs compared PDT and cryosurgery; both involved only a single session of PDT (Table 
3).
16,17
  One compared ALA-PDT in both sBCC and nBCC with cryosurgery (two freeze-thaw 
cycles, 25–30 seconds, thawing period 2–4 min).  Recurrence was evaluated by biopsy 12 
months after final treatment.
16
  The other RCT compared MAL-PDT with cryosurgery (≤20 
seconds freeze, repeated 2-3 times; Table 3).
17
  
For sBCC there was no significant difference between MAL-PDT and cryosurgery for 
initial lesion clearance or sustained clearance at 1 year, or in ALA-PDT recurrence rate at 1 
year (Table 4).  Our ITT analysis demonstrated a reduced sustained clearance at 5 years with 
single-session MAL-PDT compared with cryosurgery (RR 0.72; 95% CI 0.55–0.95; Table 4).  
This contrasted with the per-protocol analysis reported of recurrence rates of 20% with 
cryosurgery and 22% with PDT. This discrepancy is influenced by non-treatment-related AEs 
affecting seven patients treated with PDT but only two with cryosurgery. PDT gave superior 
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investigator-assessed cosmesis compared with cryosurgery at all assessment time points up 
to 5 years (RR 2.54; 95% CI 1.15–5.59; p < 0.0001; Figure 2).  Patient-assessed excellent 
cosmesis following PDT was superior to cryosurgery at 3 months (RR 2.13; 95% CI 1.15–3.92) 
but not at 1 or 2 years (Table 5).  There was no significant difference in treatment 
tolerability between PDT and cryosurgery (Table 6).
 17
 
For nBCC there was no difference in 1-year recurrence rates between cryosurgery 
and ALA-PDT.
 16
  ALA-PDT demonstrated better cosmesis than cryosurgery in sBCC and nBCC 
at 1 year (RR 3.73; 95% CI 1.96–7.07). 
PDT vs. Surgical excision 
Three studies of nBCC compared PDT with surgical excision; two studies used ALA and one, 
MAL (Table 2).  Meta-analysis showed modestly reduced rates of clearance at 3 months with 
PDT (RR 0.94; 95% CI 0.89–0.99; p = 0.03; Figure 3), and a slightly greater difference at 1 
year (RR 0.90; 95% CI 0.84–0.97; p = 0.006; Figure 4). One study compared MAL-PDT with 
surgical excision of sBCC;
18
 PDT did not show inferior rates of clearance at 3 months, but did 
so at 1 year (RR 0.91; 95% CI 0.85–0.96; p = 0.001; Table 4). 
Two nBCC studies (one MAL, one ALA) included recurrence rate at > 1  and showed 
PDT had more recurrences than excision (pooled RR 13.19; 95% CI 2.58–67.37; p = 0.002; 
Figure 5).  Clinical recurrence of sBCC after 1 year following the last treatment was 9.3% in 
the PDT arm and zero in the surgical excision arm, although 7% of excisions showed positive 
histological margins.
18
 
Those studies reporting cosmetic outcome (investigator-assessed) showed an 
advantage of PDT over surgical excision at 1-year for both sBCC (RR 1.68; 95% CI 1.32–2.14; 
p < 0.0001) and nBCC (RR 1.82; 95% CI 1.19–2.80; p = 0.006; Table 5).
18,19
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Low-to-manageable pain was greater for MAL-PDT than for excision (RR 1.81; 95% CI 
1.09–3.01; p = 0.02; Table 6).
19
 
PDT vs. Topical Treatments 
A single RCT compared MAL-PDT with repeated applications of imiquimod or fluorouracil for 
sBCC.
20-22
  This large RCT involved 601 patients, however 310 of 911 eligible patients 
declined to participate, 44% due to treatment preference.  One cycle (two treatments) of 
MAL-PDT was used, but partially cleared sBCC at 3 months were not re-treated.  There was 
no significant difference between one cycle of MAL-PDT or fluorouracil in clearance at 3 
months, 1 or 5 years.  MAL-PDT (one cycle) did not show inferior clearance rates to 
imiquimod at 3 months, but did at 1 year (RR 0.91; 95% CI 0.83–0.99; p=0.03) and 5 years 
(RR 0.81; 95% CI 0.70–0.95; p = 0.01; Table 4).   
Compared with PDT, treatment with fluorouracil or imiquimod resulted in more 
prolonged pain, which intensified throughout the treatment course.  The number of 
patients reporting severe pain per week during each treatment course, calculated using a 
cumulative measurement (2 weeks for PDT, 4 for fluorouracil, and 6 for imiquimod) 
indicated no difference in severe pain between imiquimod and MAL-PDT (RR 0.93: 95% CI 
0.61–1.41; p = 0.72), while fluorouracil demonstrated fewer episodes of severe pain than 
PDT (RR 1.93: 95% CI 1.13–3.30; Table 6). 
Suspected unexpected serious adverse reactions (SUSARs) reported with imiquimod 
included influenza-type symptoms (4%) and local wound infections (1%).  SUSAR reported 
with fluorouracil included erysipelas (2%), local wound infection (1%) and leg ulceration 
(1%).  No SUSARs were reported with PDT (see Tables 6 and S5 for pain and non-pain AEs 
respectively).
20
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PDT vs. Fractionated PDT 
Two RCTs compared conventional PDT with fractionated ALA-PDT for sBCC (for protocols 
see Table 3).
23-25
  The first involved 195 patients (573 lesions), with single-illumination ALA-
PDT as the conventional arm.
23,24
  Fractionated PDT showed greater sustained clearance, 
together with greater pain, than with single-illumination,  with the 1-year clearance being 
96% vs. 87% (RR 1.11; 95% CI 1.05–1.17; p = 0.0002), and at 5 years, 80% vs. 60% (RR 1.33; 
95% CI 1.19–1.47; p < 0.00001; Table 4).
23,24
  The second RCT, involving 162 patients with 
one primary sBCC treated per patient, used the one-cycle MAL-PDT protocol without re-
treatment of partially-responding lesions at 3 months.  Treatment failures were excised and 
scored cosmetically poor.  At 12 months’ follow-up, 13 treatment failures occurred with 
MAL-PDT and six with fractionated ALA-PDT, but this was not a statistically significant 
difference (Table 4).  Good-to-excellent cosmesis occurred more frequently with 
fractionated PDT (Table 5).  There was significantly more pain during the second illumination 
(Table 6).
25
 
PDT vs. Laser or vs. Laser-enhanced PDT 
Three RCTs compared conventional MAL-PDT and MAL-PDT with prior ablative laser 
treatment.
26-28
  The largest (286 patients), a within-patient design, compared treatments in 
patients with three recurrent nBCCs in three arms: MAL-PDT, erbium-doped yttrium-
aluminium-garnet (Er:YAG)-laser ablation, and Er:YAG-laser ablation plus MAL-PDT.
26
  The 
within-patient design precluded meta-analysis with the other RCTs.
27,28
  A 1-year clearance 
rate of approximately 75% was seen with no significant differences between the three arms 
(Table 4). Superior cosmesis of the combined treatment to PDT alone was indicated at 3, 6, 
and 9 months, while the laser alone varied (best at 3 months, equal second at 6 months, and 
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worst at 9 months); these results were all statistically significant (see Table 5 and Appendix 
S1). 
The other, smaller, trials involved facial nBCC treatments with prior ablative 
fractional laser (AFL) treatment; one used CO2-AFL, the other Er:YAG-AFL.
27,28
  The clearance 
rates at 3 months were, CO2-AFL–PDT 100% vs. PDT 88% and Er:YAG-AFL–PDT 76% vs. PDT 
43% (RR 1.78; 95% CI 1.03–3.08).
27,28
  One-year sustained clearance showed no significant 
difference in the CO2-AFL trial (CO2-laser–PDT 81% vs. PDT 64%).  The CO2-AFL–PDT versus 
PDT trial showed excellent cosmetic outcome in both arms with a tendency towards 
superior cosmesis with combined treatment (Table 5). The AEs in the two trials (Table 6) 
were typical of PDT treatment, with mild-moderate pain during illumination, quickly 
resolving after illumination, together with a range of self-limiting, transient symptoms.
27,28
 
PDT and placebo cream vs. PDT and imiquimod 
One RCT compared ALA-PDT and imiquimod versus ALA-PDT and placebo-cream for 
recurrent BCC.  This was a small study (34 patients) and the clearance results reported did 
not meet our inclusion criteria.  However, greater clearance and fewer recurrences were 
noted in the PDT plus imiquimod arm.  Cosmesis was very good in both groups (Table 5). 
Risk of bias 
The overall risk of bias for the individual outcomes of each included study varied from low 
(13, 24%), to high (35, 65%), to very high (6, 11%).  One half of the outcomes with very high 
overall risk of bias related to the within-patient study.
26
  Regarding performance bias, high 
risk predominated (39, 72%) due to blinding being precluded by nature of the treatment; 
the remainder were low risk (15, 28%).  All studies showed low risk of detection and other 
biases.  Low risk predominated for the 54 study outcomes in respect of selection (50, 93%), 
attrition (51, 94%), and outcome-reporting (51, 94%) biases (see Table S3). For outcomes 
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assessable by the GRADE criteria, the overall quality of evidence per outcome, varied from 
moderate to very low, the latter due mainly to imprecision and risk of bias (see Table S4). 
 
Discussion 
Overall, this systematic review found clearance and recurrence rates with conventional PDT 
were largely similar to alternative treatments, except for excision which showed distinctly 
improved rates.
18,19,29-32
  Modestly reduced efficacy was seen with PDT versus imiquimod in 
a study where PDT was limited to only one treatment cycle.  Strengths of PDT included its 
excellent cosmesis and lack of serious AEs. Although pain was of higher peak intensity than 
with topical treatments, it was typically of short duration and limited to the treatment 
session. 
The results from the meta-analyses and the included RCTs indicate that surgical 
excision is more effective than PDT in both sustained clearance and reducing recurrence.  
Results were not always statistically significant, with shorter follow-up times, but there was 
a consistent tendency favouring surgery in both nBCC and sBCC.  The data indicate that PDT 
and cryosurgery have similar clearance and recurrence rates.  Whilst higher clearance of 
sBCC in comparison to nBCC after PDT is widely reported
9,10
 this was not clear from the RCTs 
analysed and they were not designed to examine this; the single study involving both 
histological subtypes reported a statistically non-significant higher recurrence rate with 
superficial lesions at 1 year (38% vs. 13%).
16
 
One RCT compared MAL-PDT with imiquimod or fluorouracil for sBCC.
20-22
  Lesions 
partially responding to PDT at 3 months were regarded as treatment failures and surgically 
excised rather than re-treated.  There was no significant difference in clearance rates 
between one cycle of MAL-PDT and courses of either fluorouracil (at 3 months, 1 or 5 years) 
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or imiquimod (at 3 months), while at 1 and 5 years imiquimod showed advantage over PDT.  
Interestingly, PDT showed substantially greater sustained clearance than imiquimod in 
treating lower-extremity lesions in older patients; this was, however, a post-hoc subgroup 
analysis and requires corroboration.
21
 
Results from included trials demonstrated that, with respect to good-to-excellent 
cosmesis, PDT for nBCC was superior to placebo and to cryosurgery.  Meta-analysis of the 
two cryosurgery RCTs showed investigator-assessed excellent outcome favouring PDT.  An 
earlier systematic review concluded cosmetic outcome for PDT was significantly better than 
for surgery; this was confirmed by the four included RCTs.
33
  For sBCC, a single RCT showed 
MAL-PDT gave equivalent cosmesis to imiquimod or fluorouracil, although incompletely 
responding lesions were not re-treated with PDT but were excised, which was then defined 
as a poor aesthetic result for PDT.
16
  Cosmetic differences between therapies were smaller 
in patient assessments, and diminished with time.
17,19,31
  The cosmetic advantages of PDT 
and other topical treatments over surgery can make these more preferable to patients, 
particularly for sBCC. 
Pain is a predictable feature of a PDT session and, although generally tolerable, this 
sometimes required a break in treatment or use of infiltrative local anaesthetic.  Low or 
manageable pain was significantly worse with MAL-PDT than surgical excision, whereas 
severe AEs, such as wound dehiscence, were avoided with PDT.  Modalities differed in the 
number of treatment sessions, from a single surgical episode to 56 applications of 
fluorouracil.
16
  Pain  intensified with treatment repetition;
16 
 however, pain was primarily 
evaluated by peak rather than cumulative values, which underestimated the pain 
experienced over a course of treatment.  With PDT, pain was mostly limited to the 
irradiation period and, although peak pain was greater, it was of much shorter duration than 
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with either imiquimod or fluorouracil.  Calculation of cumulative pain showed that there 
was no difference between imiquimod and MAL-PDT, while fluorouracil was less painful 
than PDT.
20
  Recent PDT studies utilising low irradiance protocols (≤35 mWcm
-2
, compared 
with 50-200 mWcm
-2
 in this review) show reduced pain with apparent preservation of 
efficacy.
34-38
 
Treatment-related AEs, excluding pain, were widely reported in RCTs. Severe local 
AEs seldom occurred with PDT and mild-to-moderate AEs predominated.  Secondary 
infection was reported following surgery in 0-5% of patients, following fluorouracil in 2%, 
and imiquimod in 0.5%, of patients; in contrast, infection following PDT was reported in just 
a single patient throughout all trials, speculatively attributable to the potent antimicrobial 
action of topical PDT.
18,20,39
  Following PDT, effects including weeping, crusting, erosion and 
ulceration were less severe and resolved more rapidly than with cryosurgery, imiquimod or 
fluorouracil.
16,17,20
  MAL-PDT had fewer reports of moderate-to-severe local swelling, 
itching, crusting or erosion than either imiquimod or fluorouracil.
20-22
  The non-pain-related 
AEs were largely transient and of mild-to-moderate intensity after PDT and cryosurgery, and 
were less frequent following PDT.
16,17
  Of all the treatments, other than placebo cream, 
superiority was indicated for PDT with respect to non-pain AEs, particularly compared with 
imiquimod. 
 In practice, advantages of therapeutic options may vary depending on lesion 
location, lesion and patient characteristics.
12,40,41
  Patient preferences did not directly 
feature as outcomes in reviewed RCTs, but it was noted that differences in cosmesis were 
often less marked when recorded by patients than clinicians.
17,19
  A study of patient 
preferences showed cure and cosmesis were first priorities, whereby those with head/neck 
BCCs showed a willingness to trade risk of recurrence for better cosmetic outcome.
11
  A 
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systematic review of the needs and experiences of patients with skin cancer found only 
three studies of keratinocyte carcinoma; no RCT included here considered the psychosocial 
effects of BCC or its treatment, and the need for further research in this area is evident.
40,41
  
Cosmesis and AEs need to be taken into account as well as clearance, to reflect patient’s 
views.
11,42,43
 
The reviewed RCTs also included recent approaches to enhancing clearance with 
PDT, i.e. fractionation of light dose, assisted penetration of prodrug by skin pre-treatment 
with ablative fractional lasers, and combination of PDT with another modality.  Fractionated 
illumination showed higher sustained clearance of BCC than single illumination PDT, but 
greater pain was seen with fractionation, particularly during the second illumination 
23,24,25
  
The RCTs comparing conventional PDT versus PDT with laser pre-treatment showed a 
tendency towards improved clearance in the combination arm,
26-28
  while the RCT of 
conventional PDT versus PDT plus imiquimod suggested greater clearance and fewer 
recurrences in the combined treatment arm.
44
  These findings indicate that combination 
PDT warrants further study. 
Strengths of this systematic review include assessment of quality of studies using the 
Cochrane Risk of Bias tool and GRADE criteria, with presentation of ITT analyses and meta-
analyses when possible.  The scope included all RCTs comparing topical PDT directly with 
any other treatment for low-risk BCC; hence this is the most comprehensive systematic 
review of PDT for BCC to date.
45,46
  Non-English language studies were not included.  The 
major limitations reflected those of the reviewed studies, including no systematic reporting 
of patient concerns.
41,42
  A challenge in evaluating clinical trials of PDT is that protocols have 
varied including in regard to pro-drug used and incubation time; the light source, dosage 
and irradiance; and number of treatment sessions or cycles given. This severely restricted 
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the ability to pool trial data.  The included RCTs partially answered the need, identified in a 
Cochrane review 10 years ago, for head-to-head trials of effectiveness of BCC treatments, 
with long-term follow-up.
33
  Future RCTs would benefit from including PDT re-treatment of 
partially responding lesions, as in usual clinical practice, and from reporting subgroup 
analyses according to anatomical site, lesion size and patient age, particularly as major 
differences were shown between PDT and imiquimod in older patients with lower leg 
lesions. 
In conclusion, this systematic review shows that topical PDT, amongst a range of 
treatment options, can be used appropriately for low-risk BCCs.  The included RCTs 
demonstrated PDT is a favourable treatment option for cases of superficial and nodular BCC 
where patients place a high importance upon cosmesis, avoidance of ongoing AEs or 
potential for severe treatment-related complications.  New approaches to improve upon 
conventional topical PDT outcomes, namely prior use of AFL, fractionated irradiation in PDT, 
or the combination of PDT with other topical treatments, show promise and warrant further 
exploration in BCC. 
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Table 1  Trials comparator arms 
Comparator arm(s) BCC type Trial 
Placebo-PDT nBCC Foley 2009
15
 (2 RCTs) 
Cryosurgery 
sBCC 
nBCC, sBCC 
Basset-Seguin 2008
17
 
Wang 2001
16
 
Surgery 
nBCC 
nBCC 
nBCC 
sBCC 
Berroeta 2007
29
 
Mosterd 2008
30
, Roozeboom 2013
32
 
Rhodes 2004
19
, Rhodes 2007
31
 
Szeimies 2008
18
 
Topical treatments sBCC Arits 2013
20
, Roozeboom 2016
21
, Jansen 2017
22
 
Fractionated PDT 
sBCC 
sBCC 
De Haas 2006
23
, De Vijlder 2012
24
 
Kessels 2017
25
 
Laser enhanced PDT 
high-risk nBCC 
nBCC 
Haak 2015
27
 
Choi 2016
28
 
Laser enhanced PDT, and laser recurrent nBCC Smucler 2008
26
 (3 arm) 
PDT then imiquimod recurrent nBCC Osiecka 2012
44
 
 
Abbreviations: BCC, basal cell carcinoma; PDT, photodynamic therapy; RCT, randomized controlled trial; 
nBCC, nodular basal cell carcinoma; sBCC, superficial basal cell carcinoma. 
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Table 2  Study characteristics and inclusion/exclusion criteria 
Study Population (age in years) Lesion characteristics Inclusion and exclusion criteria 
Foley 2009
15
 
Parallel groups 2 RCTs 
Australia and USA 
n = 131 (150 nBCC); PDT: 47 M 19 F, mean age 66 (range 28–88), skin type I 
(41%), II (39%), III and IV (20%); Placebo-PDT: 52 M,13 F, mean age 67 
(range 39–88) skin type I (29%), II (43%), III and IV (28%) 
Primary nBCC: PDT: face/scalp 25%, neck 12%, trunk 43%, extremities 20%, largest 
diameter (mm) 8.8 (range 6–20), depth (mm) 1.3 (range 0–5.0): Placebo-PDT: face/scalp 
31%, neck 1%, trunk 45%, extremities 23%, largest diameter (mm) 9.0 (range 6–22), 
depth (mm) 1.2 (range 1–3.0) 
Standard, plus the exclusions: Periorbital, ears or nasolabial fold; 
diameter < 6 mm (any site) or > 15 mm (face or scalp) > 20 mm 
(extremities or neck) or > 30 mm (trunk), 
Basset-Seguin 2008
17
 
Parallel groups RCT 
13 European centres 
n = 120 (> 219 sBCC); Per protocol: PDT: 39 M 19 F, mean age 62 (range 25–
86), skin type I 5%, II 57%, III 33% IV 5%: Cryosurgery: 30 M, 23 F, mean age 
64 (range 38–90) skin type I 5%, II 63%, III 30% IV 2% 
Primary sBCC: PDT: face/scalp 6%, trunk/neck 72%, extremities 22%, largest diameter 
(mm) 5–10 43%, 11–19 42%, ≥ 20 16%: Cryosurgery: face/scalp 4%, trunk/neck 76%, 
extremities 20%, largest diameter (mm) 5–10 42%, 11–19 42%, ≥ 20 16% 
Standard, plus the Inclusions: Patients with ≤ 10 eligible lesions verified 
by histology and suitable for cryosurgery.  Diameter > 6 mm but < 15 mm 
(face, scalp), < 20 mm (extremities, neck), < 30 mm (trunk). 
Wang 2001
16
 
Parallel groups RCT 
Sweden 
n = 88 (88 lesions: 39 sBCC, 49 nBCC); 44 F: 44 M. Age range 42–88 nBCC and sBCC: PDT: 22 sBCC, 25 nBCC: Cryosurgery: 17 sBCC, 24 nBCC; Location: 54% 
trunk, 28% head and neck, 11% legs and 7% arms. 
Standard, plus the exclusions: daily intake of vitamins E or C, beta 
carotene, iron preparations, NSAIDs or strong analgesics at higher doses, 
BCC on nose, abdominal pain of unknown aetiology. 
Berroeta 2007
29
 
Parallel groups RCT 
UK 
n = 31 (40 nBCC); 12 F: 19 M; Median age 72 (range 50–83) nBCC; Largest diameter ≤ 20mm on anatomically noncritical sites Standard, plus the exclusions: high risk sites, recurrent BCC, BBC largest 
diameter > 20 mm 
Mosterd 2008
30
 
Roozeboom 2013
32
 
Parallel groups RCT 
Netherlands 
n = 149 (171 nBCC); 74 F: 75 M; Age, mean ± SD, 64.7 ± 13 Primary nBCC; Size (mm), mean ± SD, 9.1 ± 4.1; Location: Facial 52% (forehead or 
temple, 22.8%; nose or perinasal zone, 14.0%), nonfacial 48% (back, 14.6%) 
Standard, plus the inclusion: Maximum diameter 20 mm. and plus the 
exclusions: Life expectancy of < 5 years, Recurrent BCC, histological 
subtypes other than nodular, localisation on concave or hairy parts of the 
skin 
Rhodes 2004
19
 Rhodes 
2007
31
; 
Parallel groups RCT 
European University 
Dermatology 
Departments 
n = 101 (110 nBCC); 40 F: 61 M; Mean age: group 1; 69 (range 40–95), group 
2; 67 (range 38–82). 
Primary nBCC; Location: 50% face or scalp; 40% trunk or neck; 10% extremities. 
Largest diameter (mm), ≤ 10 60%; > 10 and < 20 31%; ≥ 20 5%. 
Standard, plus the inclusions: suitable for simple excision surgery and, 
plus the exclusions: Tumours on extremely concave areas or hairy skin.  
Patients > 10 eligible lesions, < 6 mm or > 15 mm (face or scalp), > 20 mm 
(extremities or neck), or > 30 mm (trunk); probable poor compliers; life 
expectancy < 5 years. 
Szeimies 2008
18
 
Parallel groups RCT 
Multicentre; UK/ 
Germany/ Austria/ 
Switzerland 
n = 196 (267 sBCC); 66 F: 130 M; Mean age 63.8 (range 31–92); White 
Caucasian  
Primary sBCC: Location: 65% trunk and neck; 27% extremities; 8% face and scalp.  White 
Caucasian 100% 
Diameter (mm) mean ± SD: PDT = 12.5 ± 3.7; Surgery = 12.6 ± 3.7. 
Number per patient, mean ± SD, 1.4 ± 0.9 
Standard, plus the inclusions: Largest diameter ≥ 8 mm and ≤ 20 mm.; 
and plus the exclusions Suitable for simple excision.  Midface region 
(nose, nasolabial or orbital areas), > 5, In sun damaged skin where 
surgery unsuitable due to BCC's. 
Arits 2013
20
 
Roozeboom 2016
21
 
Jansen 2017
22
;Parallel 
groups RCT; Netherlands 
n = 601 (601 sBCC); 298 F: 303 M; Mean age 63 (range 26–91); One BCC per 
patient (largest). 
Primary sBCC, histologically verified: Location: 13% head or neck; 60% trunk; 14% upper 
extremities; 13% lower extremities. 
Median size (mm
2
) 59 (range 5–5,472); median size (mm
2
) was 52 in MAL-PDT group and 
63 in both imiquimod and fluorouracil groups. 
Standard, plus the exclusions: tumour on scalp 
Smucler 2008
26
 
Within patient RCT 
Czech Republic 
n = 286 (858 recurrent nBCC); 94 F: 192 M; Age, mean ± SD, 65.1 ± 7.3; Skin 
type I 29%, II 69.9%, III 1.1% 
Recurrent nBCC Inclusions: At least 3 recurring nBCCs (histologically verified). At least 
30mm between tumours.  Refractory to at least one surgical excision, 
cryosurgery or laser ablation. Exclusions: Inability to attend regular 
checkups (patients from abroad were excluded from the study). 
Haak 2015
27
 
Parallel groups RCT 
Denmark 
n = 32 (32 nBCC); 17 F: 15 M; Median age 66 (range 57–73.5) Skin type II 
(20), III (12) 
Primary nodular facial ‘high-risk’ BCC which was histologically confirmed.  Location: 17% 
nose; 25% forehead; 9% cheek; 9% oral area; 9% periorbital area. Single lesion per 
patient. Median tumour size: AFXL-PDT, 7 mm; PDT, 8.5 mm. 
Standard, plus the inclusions: High-risk facial tumour due to either (i) 
diameter > 15mm, (ii) located in high-risk facial H zone, or (iii) located on 
severely sun damaged skin with ≥ 1 actinic lesions requiring treatment. 
and, plus the exclusions: Skin type IV–VI, risk of poor compliance 
Page 25 of 97 British Journal of Dermatology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
26 
 
Study Population (age in years) Lesion characteristics Inclusion and exclusion criteria 
Choi 2016
28
 
Parallel groups RCT 
South Korea 
n = 39 (42 nBCC): MAL-PDT: 7 F: 12 M; Age, mean ± SD, 63.3 ± 10.7; Skin 
type: III 15%, IV 65%, V 20%: Er:YAG AFL-PDT: 11 F: 9 M ; Age, mean ± SD, 
66.9 ± 9.6; Skin type III 11%, IV 75%, V 16% 
Primary nBCC of maximum depth ≤ 2 mm; histologically verified. Standard, plus the inclusions: Patients where surgical excision would be 
difficult because of bleeding abnormalities or cardiac problems. and, plus  
the exclusions: Midface region, nose orbital areas or ears; longest 
diameter > 15mm; > 5 eligible lesions; active systemic infectious disease; 
indication of poor compliance 
Osiecka 2012
44
 
Parallel groups RCT 
Poland 
n = 34 (34 recurrent); Age range 50–68. Recurrent BCC, confirmed histopathologically: Location: Face (nose, nasolabial sulcus, 
cheek, suborbital region) 
Mean diameter 5 mm 
Standard, plus the inclusions: Facial BCC previously treated with 
cryosurgery, laser therapy or surgical excision without satisfactory 
results. Good health and, plus the exclusions: Systemic disease. 
De Haas 2006
23
 
Parallel groups RCT 
Netherlands 
n = 155 patients (505 sBCC): Single illumination, Age, mean 57 (range 32–
81): Fractionated illumination, Age, mean 56 (range 31–83)  
sBCC Inclusions: Clinically or histologically diagnosed sBCC (with at least one 
histologically diagnosed primary sBCC per patient). Exclusions: Child or 
not white-Caucasian. 
De Vijlder 2012
24
 n = 195 patients (573 sBCC) (plus further 50 patients with 172 sBCC treated 
by fractionated illumination): Single illumination, Age, mean 56.7 (range 
31–88): Fractionated illumination, Age, mean 56.9 (range 32–84): 
Fractionated illumination with later enrolment, Age, mean 65.5 (range 39–
90); 
sBCC Inclusions: Clinically or histologically diagnosed sBCC (with at least one 
histologically diagnosed primary sBCC per patient). Exclusions: Child or 
not white-Caucasian. 
Kessels 2017
25
 n = 162 patients (162 sBCC): MAL-PDT: 45 F; 35 M: Age, mean 63.6 (range 
28-83): ALA 2-fold fractionated illumination: 42 F; 40 M: Age, mean 65.9 
(range 38–85) 
Primary sBCC: MAL-PDT: head/neck 1%, trunk 73%, upper extremities 8.8%, lower 
extremities 18%: tumour size mm, mean ± SD; 11.2 ± 7.1 ALA-PDT 2-fold: head/neck 7%, 
trunk 45%, upper extremities 16%, lower extremities 17%: tumour size mm, mean ± SD; 
10.8 ± 5.3 
Standard, plus the inclusions: One sBCCper patient selected (largest-
diameter eligible). and, plus the exclusions: Prior treatment at the same 
site. sBCC localized in the hairy scalp and convex or concave areas such as 
the ears or fingers. 
 
Abbreviations: M, male; F, female; n, number; skin type, Fitzpatrick skin type; MAL, methyl aminolaevulinate; ALA, 5-aminolaevulinic acid; PDT, photodynamic therapy; BCC, basal cell carcinoma; PDT, photodynamic therapy; RCT, randomized controlled trial; nBCC, 
nodular basal cell carcinoma; sBCC, superficial basal cell carcinoma; NSAID, nonsteroidal anti-inflammatory drug; SD, standard deviation. Standard: inclusion when ≥ 18 years, primary histologically confirmed nBCC or sBCC, not previously treated. Exclusion: anogenital 
area, areas within 1 cm of H-zone, pigmented or morphoeaform or infiltrative BCC, dermatological conditions that interfere with treatment, genetic skin disorders, immunosuppressive therapy, pregnant or breastfeeding women. 
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Table 3  Treatment protocols for included studies 
Study BCC Conventional PDT Treatment 
[Skin preparation; Prodrug; Incubation (hours); Wavelength (nm); Irradiance (mWcm
-2
); Sessions; Light dose 
per session (Jcm
-2
); PDT re-treatment] 
Comparator Treatment 
Foley 2009
15
 nodular Surface debridement, no LA; MAL (Metvix); 3; 570–670, noncoherent; 50–200; 2, (1 week apart); 75; 2 
sessions if partial response (≥ 50% but < 100%) at 3 months, 22% of patients. 
Placebo-PDT: lesion debulked with curette, PDT protocol with placebo cream. 
Basset-Seguin 2008
17
 superficial Surface scrape, no LA; MAL (Metvix); 3; 570–670, noncoherent; not stated; 1; 75; 2 sessions if noncomplete 
response at 3 months, 30% of lesions  
Cryosurgery: ice field formation with a 3 mm rim of healthy tissue. Ice field maintained for 20 seconds. 
Double freeze–thaw cycle. 
Wang 2001
16
 nodular and 
superficial 
Surface scrape, no LA; ALA 20% (nonproprietary); 6; 635, laser; 80 ± 20; 1; 60; 1 session if noncomplete 
clinical response at 4, 8, or 12 months or histological response at 3 months after final treatment, 30% of 
lesions 
Cryosurgery: 2 freeze thaw cycles comprising 25–30 seconds freeze and 2–4 minutes thaw 
Berroeta 2007
29
 nodular Surface scrape, no LA, diagnostic punch biopsy for PDT only; ALA 20% (nonproprietary); 6; 635, laser; 120; 1; 
125; If failure, re-treat at 3 months (1 session) 
Surgery: under LA; excision with margins as recommended.
47
 
Mosterd 2008
30
 
Roozeboom 2013
32
 
nodular Partially debulked (to level of skin) under LA, 3 weeks prior to PDT; ALA 20% (nonproprietary); 4; 585–720, 
noncoherent; 100; 2 , (1 hour apart); fractionated, 75 + 75; No, incomplete response or recurrent tumour was 
re-treated surgically 
Surgery: Tumour excised with a 3 mm margin under LA.  Re-excised if tumour present at margins (lateral 
or deep) and deemed treatment failure. 
Rhodes 2004
19
 
Rhodes 2007
31
 
nodular Surface scrape, no LA; MAL (Metvix); 3; 570–670, noncoherent; 50–200; 2, (1 week apart); 75; If failure, re-
treat at 3 months 
Surgery: Elliptical excision surgery with ≥ 5 mm margins under LA.  
Szeimies 2008
18
 superficial Surface scrape, no LA; MAL (Metvix); 3; 630 ± 5, noncoherent; 62–88; 2, (1 week apart); 37; If failure, re-treat 
at 3 months 
Surgery: elliptical excision with 3 mm margin. 
Arits 2013
20
 
Roozeboom 2016
21
 
Jansen 2017
22
 
superficial Surface scrape, no LA, ; MAL (Metvix); 3; ≈ 630, noncoherent; ≈ 88; 2, (1 week apart); 37; No Imiquimod: applied 5 days a week for 6 weeks. 
Fluorouracil: applied twice daily for 4 weeks.  
Smucler 2008
26
 recurrent 
nodular 
None mentioned; MAL (Metvix); 3; 630 ± 5, noncoherent; not stated; 2, (1 week apart); 37; No Er:YAG laser: topical anaesthetic applied for 1 hour. Ablation using Er:YAG AFL usually with 600–1000 mJ 
at 7 Hz. Infiltration of LA and bipolar electrocoagulation where necessary. 
Er:YAG laser and PDT: Laser as above, with MAL-PDT, as per protocol on left, subsequently. 
Haak 2015
27
 nodular Partially debulked under LA , ; MAL (Metvix); 3; 630 ± 5, noncoherent; ≈ 77; 2, (7–10 days apart); 37; No CO2 AFL PDT: LA injection with partial debulking followed by CO2 AFL with 2 stacked pulses of 40 mJ/pulse 
at density of 5% on tumour area plus 5 mm margin.  Treatment sessions were performed twice with a 7-
10 days interval. 
Choi 2016
28
 nodular None; MAL (Metvix); 3; 630 ± 5, noncoherent; not stated; 2, (1 week apart); 37; No Er:YAG AFL PDT: 
Topical LA applied prior to Er:YAG AFL, 2940 nm with a 550 μm ablation depth, 22% treatment density and 
a single pulse. Immediately following AFL, a single session of MAL-PDT as per protocol on left. 
Osiecka 2012
44
 recurrent None mentioned; ALA (Levulan); 4; 635 ± 20, noncoherent; 56; 2, (2 days apart); 100; No PDT and Imiquimod: PDT protocol followed by imiquimod cream, 3 days post irradiation and applied twice 
per week for 5 weeks.  The placebo-PDT arm used vehicle cream instead of imiquimod. 
De Haas 2006
23
 
De Vijlder 2012
24
 
superficial Surface scrape, LA in ALA preparation; ALA 20% (nonproprietary with 2% LA); 4 vs 4 + 6; Diode laser (630), LED 
(633) Broadband (590–650); 50; 1; 75 vs fractionated 20 + 80, (2 hours apart); Re-treated lesions excluded 
from analysis 
Fractionated PDT: twofold ALA-PDT illumination 20 Jcm
-2
 and 80 Jcm
-2
 after 4 and 6 hours respectively. 
Kessels 2017
25
 superficial None mentioned; MAL (Metvix); 3; 630 ± 5, LED; 75; 2 (1week apart); 75; Residual tumour at 3 months 
considered treatment failure and excised. 
Fractionated PDT: twofold ALA-PDT illumination 20 Jcm
-2
 and 80 Jcm
-2
 after 4 and 6 hours respectively. 
 
Abbreviations: PDT, photodynamic therapy; BCC, basal cell carcinoma; LA, local anaesthetic; MAL, methyl aminolaevulinate; ALA, 5-aminolaevulinic acid; Er:YAG, erbium-doped yttrium-aluminium-garnet; AFL, ablative fractional laser; LED, light emitting 
diode light source 
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Table 4  Clearance and recurrence rates 
Study (Comparator) Assessment of clearance and recurrence Clearance at 3 months Sustained clearance at 1 year Sustained clearance at 5 years Recurrence rate ≥ 1 year 
Foley 2009
15
 (Placebo-PDT) Assessed clinically 3 months after initial treatment or retreatment; 
confirmed histologically by independent laboratory (blinded). Excised at 3 
months (clinical nonresponders), or 6 months (clinical responders), after 
last treatment. 
MAL-PDT 73% vs Placebo 27%  RR 
2.75 95%CI 1.84–4.10, 
p < 0.00001 
No data meeting extraction criteria 
(all excised < 1 year). 
No data meeting extraction criteria (all 
excised < 1 year). 
No data meeting extraction criteria (all 
excised < 1 year). Variable of interest was 
histologically verified complete response 6 
months after last treatment. 
Basset-Seguin 2008
17
 
(Cryosurgery) 
Clinical evaluation of lesion recurrence at 1,2,3,4 and 5 years after last 
treatment. 
MAL-PDT 90% vs Cryo 90%  RR 
1.01 95%CI 0.89–1.14, p = 0.90 
MAL-PDT 91% vs Cryo 92% RR 0.99 
95%CI 0.88–1.11, p = 0.82 
MAL-PDT 57% vs Cryo 79% RR 0.72 
95%CI 0.55–0.95, p = 0.02 
1–2 years MAL-PDT 14% vs Cryo 6% RR 
2.20 95%CI 0.66–8.01, p = 0.23 
1–3 years MAL-PDT 22% vs Cryo 6% RR 
3.45 95%CI 1.02–11.62, p = 0.05 
1–4 years MAL-PDT 22% vs Cryo 6% RR 
3.45 95%CI 1.02–11.62, p = 0.05 
1–5 years MAL-PDT 22% vs Cryo 8% RR 
2.59 95%CI 0.88–7.58, p = 0.08 
Wang 2001
16
 (Cryosurgery) Histological assessment of punch biopsies 12 months after initial 
treatment. 
No data meeting extraction 
criteria 
No data meeting extraction criteria No data meeting extraction criteria sBCC 1-year ALA 36% vs Cryo 6% RR 6.18 
95%CI 0.85–44.78, p = 0.07 
nBCC 1-year ALA 12% vs Cryo 21% RR 0.58 
95%CI 0.15–2.15, p = 0.41 
Berroeta 2007
29
 (Surgery) PDT repeated at 3 months if BCC clinically evident.  If at 6 months BCC 
persists referred for alternative treatment. 
No data meeting extraction 
criteria 
MAL-PDT 61% vs Surgery 79%  RR 
0.78 95%CI 0.52–1.18 
No data meeting extraction criteria No data meeting extraction criteria 
Mosterd 2008
30
 Roozeboom 
2013
32
 (Surgery) 
At 3, 6, 12, 18, 24, 36, 48 and 60 months, recurring tumour (histologically 
confirmed BCC within 5mm of scar) recorded. Patients lost to follow-up 
censored at last examination.  Median follow-up 67 months (range 0–
106) 
ALA 93% vs Surgery 98% RR 0.95 
95%CI 0.89–1.02 
ALA 87% vs Surgery 96%  RR 0.90 
95%CI 0.82–0.99 
ALA 53% vs Surgery 74%  RR 0.71 95%CI 
0.56–0.91, p = 0.006 
1–2 years ALA 7% vs Surgery 0% RR 13.20 
95%CI 0.74–234.59 
1–5 years ALA 17% vs Surgery 0% RR 30.00 
95%CI 1.81–497.72, p = 0.02 
Rhodes 2004
19
 Rhodes 2007
31
 
(Surgery) 
Complete response assessed at 3 months after last treatment by the 
same investigator.  Lesions assessed annually for 5 years.  Any clinical 
recurrence was histologically confirmed. 
MAL-PDT 91% vs Surgery 98% RR 
0.92 95%CI 0.84–1.02 
MAL-PDT 92% vs Surgery 98%  RR 
0.94 95%CI 0.85–1.03 
MAL-PDT 60% vs Surgery 71% RR 0.83 
95%CI 0.63–1.11, p = 0.21 
1–2 years MAL-PDT 7% vs Surgery 2% RR 
3.14 95%CI 0.37–31.60 
1–5 years MAL-PDT 10% vs Surgery 4% RR 
2.65 95%CI 0.54–13.05, p = 0.23 
Szeimies 2008
18
 (Surgery) Visits at screening, baseline, 1, 13, 26 and 52 weeks (phone call week 3).  
If 2 MAL-PDT cycles, visits also at weeks 14, 39, 65 (phone call week 15). 
MAL-PDT 87% vs Surgery 89% RR 
0.99 95%CI 0.90–1.08, p = 0.76 
MAL-PDT 91% vs Surgery 100%  RR 
0.91 95%CI 0.85–0.96, p = 0.001 
No data meeting extraction criteria 1 year MAL-PDT 9% vs Surgery 0%. The 11 
(9%) MAL-PDT lesions recurring at 1 year 
comprised 4/15 (27%) face/scalp; 3/69 
(4%) trunk/neck; 4/34 (12%) extremities. 
Arits 2013
20
 Roozeboom 2016
21
 
Jansen 2017
22
 (Imiquimod or 
fluorouracil) 
Clinically assessed (blinded) at 3 and 12 months post-treatment. 
Treatment failures histologically confirmed via 3mm punch biopsy.  
Median follow-up period 35 months (range 1–54 months). 
MAL-PDT 82% vs IMQ 86%  RR 
0.95 95%CI 0.87–1.04, p = 
0.26  MAL-PDT 82% FU 87% RR 
0.94 95%CI 0.87–1.03, p = 0.18 
MAL-PDT 82% vs IMQ 90%  RR 0.91 
95%CI 0.83–0.99, p = 0.03  MAL-
PDT 82% vs FU 89%  RR 0.92 95%CI 
0.85–1.01, p = 0.09 
Sustained clearance at 3 years MAL-PDT 
70% vs IMQ 84% RR 0.84 95%CI 0.74–
0.94, p = 0.03: MAL-PDT 70% vs FU 79% 
RR 0.89 95%CI 0.78–1.00, p = 0.06 
Sustained clearance at 5 years MAL-PDT 
59% vs IMQ 73% RR 0.81 95%CI 0.70–
0.95, p = 0.01 : MAL-PDT 59% vs FU 67% 
RR 0.88 95%CI 0.75–1.04, p = 0.14 
No data meeting extraction criteria 
Smucler 2008
26
 (Er:YAG laser, 
Er:YAG laser/PDT) 
Clinical evaluation at 3, 6 and 12 months. Independent evaluation of 
response at 12 months via dermoscopic images and histological 
examination of a shave biopsy sample.  
Er:YAG laser/PDT 87% vs MAL-
PDT 86% RR 1.01 95%CI 0.94–
1.08, p = 0.81 
Er:YAG laser/PDT 77% vs MAL-PDT 
75% RR 1.04 95%CI 0.94–1.14, p = 
0.49 
No data meeting extraction criteria No data meeting extraction criteria 
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Study (Comparator) Assessment of clearance and recurrence Clearance at 3 months Sustained clearance at 1 year Sustained clearance at 5 years Recurrence rate ≥ 1 year 
Haak 2015
27
 
(CO2-AFL/MAL-PDT) 
At 3, 6, 9 and 12 months treatment response and recurrence assessed by 
photography (blinded). If noncomplete or uncertain response biopsy 
performed.  Recurrent lesions excluded and treated according to national 
guidelines.  At 12 months biopsies from the centre of treated areas 
histologically assessed. 
AFL-MAL-PDT 100% vs MAL-PDT 
88% RR 1.14 95%CI 0.92–1.41, p = 
0.24 
Per patient AFL-MAL-PDT 81% vs 
MAL-PDT 64%  RR 1.26 95%CI 
0.80–1.99, p = 0.31 
Per lesion AFL-MAL-PDT 63% vs 
MAL-PDT 64% RR 0.97 95%CI 0.56–
1.68, p = 0.92 
Study terminated at 1 year No data meeting extraction criteria 
Choi 2016
28
 
(Er:YAG-AFL/ALA-PDT) 
Patients photographed at baseline, 1 week, 3 months and 12 months.  
Efficacy assessed based on inspection, dermoscopy, photography, 
palpation and histologic findings.  Biopsies performed if clinical doubt.  All 
cases of complete response reviewed at 12 months.  
AFL/ALA-PDT 76% vs MAL-PDT 
43% RR 1.78 95%CI 1.03–3.08, p = 
0.04 
No data meeting extraction criteria No data meeting extraction criteria AFL/ALA-PDT 6% vs MAL-PDT 56%  RR 0.11 
95%CI 0.02–0.82, p = 0.03 
Osiecka 2012
44
 
(PDT/imiquimod) 
Clinical examination and photodynamic diagnosis (PDD). PDD repeated 
for 6 weeks, then 2 monthly to 14 months. 
No data meeting extraction 
criteria 
No data meeting extraction criteria No data meeting extraction criteria Per patient > 1-year ALA-PDT/IMQ 25% vs 
ALA-PDT 40% RR 0.63 95%CI 0.22–1.75, p 
= 0.37 
De Haas 2006
23
 De Vijlder 
2012
24
 (Fractionated PDT) 
Clinical response assessed by staff.  Patients reviewed four times in year 
1, then twice yearly until year 5. 
No data meeting extraction 
criteria 
ALA-PDT (fractionated) 96% vs 
ALA-PDT (single) 87% RR 1.11 
95%CI 1.05–1.17, p = 0.0002 
ALA-PDT (fractionated) 80% vs ALA-PDT 
(single) 60% RR 1.33 95%CI 1.19–1.47, 
p < 0.00001 
No data meeting extraction criteria 
Kessels 2017
25
 (Fractionated 
ALA-PDT) 
Clinical response assessed by two investigators (blinded).  Patients 
assessed at baseline, 3 and 12 months post-treatment. 
Frac-ALA-PDT 93% vs MAL-PDT 
94% RR 0.99 95%CI 0.91–1.07, p = 
0.79 
Frac-ALA-PDT 96% vs MAL-PDT 
87% RR 1.11 95%CI 1.00-1.22, p = 
0.05 
No data meeting extraction criteria No data meeting extraction criteria 
 
Abbreviations: MAL, methyl aminolaevulinate; ALA, 5-aminolaevulinic acid; PDT, photodynamic therapy; BCC, basal cell carcinoma; CI, confidence interval; RR, risk ratio; FU, 5-fluorouracil; IMQ, imiquimod; AFL, Ablative Fractional Laser; Er:YAG, Erbium-doped 
Yttrium-Aluminium-Garnet; CO2-AFL, carbon dioxide Ablative Fractional Laser; Frac, Fractionated. 
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Table 5  Cosmetic outcome 
Study 
(Comparator) 
Assessment method Investigator assessed cosmetic outcome Patient assessed cosmetic outcome 
Foley 2009
15
 
(Placebo-PDT) 
Investigator: 4-point scale* 6 months, good-excellent, MAL-PDT 56% vs Placebo 19% RR 3.00: 95%CI 1.80–
5.01, p < 0.0001 
No data meeting extraction criteria 
Basset-Seguin 
2008
17
 
(Cryosurgery) 
Investigator: Complete response on 4-point scale*, ‘excellent’ (no scarring, atrophy, 
induration, no/slight erythema/dyspigmentation), ‘good’ (no scarring, atrophy, 
induration, moderate redness/pigmentation change), ‘fair’ (slight/moderate 
scarring, atrophy/induration), ‘poor’ (extensive scarring, atrophy, induration). 
Patient: assessed as, excellent, good, fair, poor. 
3 months, excellent, MAL-PDT 27% vs Cryo 3% RR 7.95: 95%CI 1.92–32.92, p < 
0.004 
1 year, excellent, MAL-PDT 32% vs Cryo 12% RR 2.67: 95%CI 1.22–5.85 
2 years, excellent, MAL-PDT 40% vs Cryo 7% RR 5.85: 95%CI 2.17–15.78, p = 
0.0005 
3 years, excellent, MAL-PDT 31% vs Cryo 9% RR 3.55: 95%CI 1.42–8.90, p = 0.007 
4 years, excellent, MAL-PDT 31% vs Cryo 9% RR 3.55: 95%CI 1.42–8.90, p = 0.007 
5 years, excellent, MAL-PDT 31% vs Cryo 12% RR 2.54: 95%CI 1.15–5.59, p = 0.02 
3 months, excellent, MAL-PDT 40% vs Cryo 19% RR 2.13: 95%CI 
1.15–3.92, p = 0.02 
1 year, excellent, MAL-PDT 35% vs Cryo 24% RR 1.47: 95%CI 0.83–
2.59, p = 0.18 
2 years, excellent, MAL-PDT 37% vs Cryosurgery 26% RR 1.43: 
95%CI 0.83–2.47, p = 0.19 
Wang 2001
16
 
(Cryosurgery) 
Physician and 2 scientists (blinded) assessed photographs and video for overall 
impression (excellent, good, acceptable, blemished) based on dyspigmentation and 
scarring (none, slight, obvious). 
Excellent, 1 year, MAL-PDT 45% vs Cryo 7% RR 6.11: 95%CI 1.96–19.00 No data meeting extraction criteria 
Berroeta 2007
29
 
(Surgery) 
Independent nonmedical assessors (10 men, 10 women) evaluation of clinical 
photographs.  Scar severity 4 point scale (excellent/none to very poor) at 3 , 6, 12 
months after last treatment. 
No data meeting extraction criteria. Reports (male/female assessors) mean scar 
severity: surgery, 2.07/2.53; PDT, 1.94/2.23. 
No data meeting extraction criteria 
Mosterd 2008
30
 
Roozeboom 
2013
32
 (Surgery) 
Cosmetic outcome not assessed  No data meeting extraction criteria No data meeting extraction criteria 
Rhodes 2004
19
 
Rhodes 2007
31
 
(Surgery) 
Investigator assessment, 4-point scale*, 3 months, 1, 2, and 5 years. Patient 
assessment: 3, 12, 24 months, 4-point scale: excellent, good, fair, poor. 
3 months, good-excellent, MAL-PDT 72% vs Surgery 32% RR 2.26: 95%CI 1.44–
3.54, p = 0.0004 
1 year, good-excellent, MAL-PDT 66% vs Surgery 36% RR 1.82: 95%CI 1.19–2.80, 
p = 0.006 
2 years, good-excellent, MAL-PDT 48% vs Surgery 34% RR 1.41: 95%CI 0.86–2.31, 
p = 0.17 
5 years, good-excellent, MAL-PDT 54% vs Surgery 40% RR 1.34: 95%CI 0.87–2.06, 
p = 0.19 
3 months, good-excellent, MAL-PDT 78% vs Surgery 79% RR 0.99: 
95%CI 0.80–1.22, p = 0.93 
1 year, good-excellent, MAL-PDT 82% vs Surgery 77% RR 1.07: 
95%CI 0.87–1.31, p = 0.51 
2 years, good-excellent, MAL-PDT 56% vs Surgery 57% RR 0.97: 
95%CI 0.69–1.38, p = 0.89 
Szeimies 2008
18
 
(Surgery) 
Primary outcome: investigator assessment, 12 months, 4-point scale (poor, fair, 
good, excellent). 
Secondary outcomes: investigator assessment, 3, 6 months; patient assessment, 3, 
6, 12 months (same scale). 
3 months, good-excellent, MAL-PDT 77% vs Surgery 58% 
6 months, good-excellent, MAL-PDT 92% vs Surgery 59% 
1 year, good-excellent, MAL-PDT 77% vs Surgery 46% RR 1.68: 95%CI 1.32–2.14, 
p < 0.0001 
3 months, good-excellent, MAL-PDT 94% vs Surgery 81% 
6 months, good-excellent, MAL-PDT 98% vs Surgery 83% 
1 year, good-excellent, MAL-PDT 98% vs Surgery 8%3 
Arits 2013
20
 
Roozeboom 
2016
21
 Jansen 
2017
22
 (IMQ, FU) 
At 12 months observer (blinded) assessment, four-point scale (excellent, good, fair, 
poor).  Treatment failures defined poor as re-treated surgically. 
1 year, good-excellent, MAL-PDT 57% vs IMQ 57% RR 1.01: 95%CI 0.85–1.19, 
p = 0.94 
1 year, good-excellent, MAL-PDT 57% vs FU 55% RR 1.04: 95%CI 0.88–1.24, 
p = 0.66 
No data meeting extraction criteria 
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Study 
(Comparator) 
Assessment method Investigator assessed cosmetic outcome Patient assessed cosmetic outcome 
Smucler 2008
26
 
(Er:YAG laser, 
Er:YAG laser/PDT) 
12 months observer (blinded) assessed, 4-point scale (1) no damage (2) slight 
pigmentation changes/palpable healing (3) minor changes in relief/erythema, 
minor residues of necrotic tissue, minor recurrence (4) fundamental relief damage, 
scarring, extensive residues of necrotic tissue, ulcer, full recurrence. 
3 months, aesthetic result, mean ± SD: Er:YAG-laser-PDT, 2.00 ± 0.57; Er:YAG-
laser, 1.62 ± 0.76; p < 0.00001: Er:YAG-laser-PDT, 2 ± 0.57; MAL-PDT, 3.17 ± 0.57; 
p < 0.00001. 
6 months, aesthetic result, mean ± SD: Er:YAG-laser-PDT, 1.17 ± 0.24; Er:YAG-
laser, 1.50 ± 0.70; p < 0.00001: Er:YAG-laser-PDT, 1.17 ± 0.24; MAL-PDT, 1.50 ± 
0.43; p < 0.00001. 
9 months, aesthetic result, mean ± SD: Er:YAG-laser-PDT, 1.23 ± 0.44; Er:YAG-
laser, 1.83 ± 0.95; p < 0.00001: Er:YAG-laser-PDT, 1.23 ± 0.44; MAL-PDT, 1.67 ± 
0.76; p < 0.00001. 
No data meeting extraction criteria 
Haak 2015
27
 
(CO2-AFL/PDT) 
Dermatologist (blinded) assessment, 3, 6, 9 and 12 months (scarring, 
hypopigmentation, hyperpigmentation, overall cosmetic outcome referred to 
clinical photographs and baseline template). 
Patients evaluation: each visit. 
Per patient, 3 months, excellent: AFL-PDT 69% vs MAL-PDT 56% RR 1.22: 95%CI 
0.71–2.11, p = 0.47 
Per patient, 6 months, excellent: AFL-PDT 75% vs MAL-PDT 38% RR 2.00: 95%CI 
1.00–4.00, p = 0.05 
Per patient, 9 months, excellent: AFL-PDT 50% vs MAL-PDT 44% RR 1.14: 95%CI 
0.54–2.40, p = 0.72 
Per patient, 1 year, excellent: AFL-PDT 50% vs MAL-PDT 25% RR 2.00: 95%CI 
0.75–5.33, p = 0.17 
Per patient, 3 months, excellent: AFL-PDT 81% vs MAL-PDT 50% 
RR 1.63: 95%CI 0.94–2.80, p = 0.08 
Per patient, 6 months, excellent: AFL-PDT 75% vs MAL-PDT 50% 
RR 1.50: 95%CI 0.85–2.64, p = 0.16 
Per patient, 9 months, excellent: AFL-PDT 63% vs MAL-PDT 50% 
RR 1.25: 95%CI 0.67–2.32, p = 0.48 
Per patient, 1 year, excellent: AFL-PDT 56% vs MAL-PDT 44% RR 
1.29: 95%CI 0.64–2.60, p = 0.48 
Choi 2016
28
 
(Er:YAG-AFL/PDT) 
Investigator assessed complete responses, 3 or 12 months, 4-point scale*. Per lesion, excellent, 12 months: AFL-PDT 57% vs MAL-PDT 57% RR 1.00: 95%CI 
0.59–1.69, p = 1.00 
No data meeting extraction criteria 
Osiecka 2012
44
 
(PDT/IMQ) 
No formal assessment of cosmesis  No data meeting extraction criteria No data meeting extraction criteria 
De Haas 2006
23
 De 
Vijlder 2012
24 
(Fractionated PDT) 
No formal assessment of cosmesis No data meeting extraction criteria No data meeting extraction criteria 
Kessels 2017
25
 
(Fractionated 
ALA-PDT) 
2 independent investigators (blinded), four-point scale (poor, fair, good or 
excellent).Treatment failures scored poor, as excised. 
Good-excellent, Frac ALA-PDT 71% vs MAL-PDT 77% vs Surgery 60% RR 1.18 
95%CI 0.94–1.48, p = .0.15 
No data meeting extraction criteria 
 
*scale as in Basset-Seguin
17
; Abbreviations: MAL, methyl aminolaevulinate; ALA, 5-aminolaevulinic acid; PDT, photodynamic therapy; CI, confidence interval; RR, risk ratio; FU, 5-fluorouracil; IMQ, imiquimod; AFL, Ablative Fractional Laser;  
Er:YAG, Erbium-doped Yttrium-Aluminium-Garnet; CO2-AFL, carbon dioxide Ablative Fractional Laser; Frac, Fractionated. SD, standard deviation 
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Table 6  Pain 
Study (Comparator) Analgesia Assessment of pain  Severe pain* Low or manageable pain 
Foley 2009
15
 (Placebo-PDT) None stated During treatment and follow-up, nurse (blinded) 
noted severity, duration, analgesia. 
MAL-PDT 0% vs Placebo 0% MAL-PDT 90% vs Placebo 66% 
RR 1.37: 95%CI 1.14–1.66, p < 0.001 
Basset-Seguin 2008
17
 (Cryo) None stated Severity and cause recorded at each follow-up, 
until 3 months after final treatment. 
MAL-PDT 5% vs Cryo 2% 
RR 2.81: 95%CI 0.30–26.22 
MAL-PDT 75% vs Cryo 72% 
RR 1.02: 95%CI 0.83–1.27, p < 0.83 
Wang 2001
16
 (Cryo) PDT: water sprayed if pain.  Single 
lesion in PDT group sprayed with 
LA. 
In first week after treatment patient completed a 
VAS. 
MAL-PDT 2% vs Cryo 0% 
RR 2.63: 95%CI 0.11–62.73 
No data meeting extraction criteria 
Berroeta 2007
29
 (Surgery) Surgery under infiltrative LA. No 
anaesthesia stated in PDT. 
Patients assessed (VAS) during, immediately 
after, 3, 6, 24, and 48 hours and 1 week later. 
No data meeting extraction criteria.  No data meeting extraction criteria 
Mosterd 2008
30
 Roozeboom 
2013
32
 (Surgery) 
Surgery under infiltrative LA. Documented at review No data meeting extraction criteria No data meeting extraction criteria 
Rhodes 2004
19
 Rhodes 2007
31
 
(Surgery) 
Surgery under infiltrative LA. 
No LA used in PDT. 
Severity, duration, and pain relief documented 
after illumination. 
One MAL-PDT patient discontinued treatment due to severe burning 
sensation; resolved later in day without medical intervention. Otherwise 
mild to moderate intensity; all resolved < 1 day. 
MAL-PDT 54% vs Surgery 30% 
RR 1.81: 95%CI 1.09–3.01, p = 0.02 
Szeimies 2008
18
 (Surgery) Mini desk fans available during 
irradiation. 
Severity, duration, and need for pain relief 
documented at each visit.  
3% of the patients needed illumination pausing due to pain at second 
session of each cycle, but none at start of first cycle. 
 
Arits 2013
20
 Roozeboom 2016
21
 
Jansen 2017
22
 (IMQ or FU) 
 Patient recorded weekly, and on first and second 
PDT session, maximum score for pain and burning 
sensation on a VAS. 
MAL-PDT 9% vs IMQ 7% ; RR 0.93: 95% CI 0.61–1.41, p = 0.72: MAL-PDT 
9% vs FU 4% ;: RR 1.93: 95% CI 1.13–3.30, p = 0.02. MAL-PDT severe pain 
mostly during illumination. 
MAL-PDT 85% vs IMQ 85% ;  RR 1.00: 95%CI 0.92–1.08, p = 
0.96 : MAL-PDT 85% vs FU 88% 
RR 0.97: 95%CI 0.89–1.05, p = 0.40 
Smucler 2008
26
 (Er:YAG laser, 
Er:YAG laser /PDT) 
Prior to laser, topical LA and, as 
needed, infiltrative LA. 
None described  No data meeting extraction criteria No data meeting extraction criteria 
Haak 2015
27
 (CO2-AFL/PDT) Prior to AFL, infiltrative LA used. During illumination and at assessments, patients 
scored pain on numerical scale. 
No data meeting extraction criteria No data meeting extraction criteria 
Choi 2016
28
 (Er:YAG-AFL/PDT) Prior to AFL, topical anaesthetic 
applied. 
During illumination, patients evaluated pain on a 
VAS.  Reports spontaneous or at visits at 1 week, 
3 months, and 1 year. 
No severe pain reported; no patients discontinued the study because of 
pain. 
Pain mild to moderate during illumination, after immediately 
lessened, resolving in a few hours. VAS scores during 
illumination were similar in each arm. 
Osiecka 2012
44
 (PDT/IMQ) None described None described None described None described 
De Haas 2006
23
 De Vijlder 
2012
24
 (Fractionated PDT) 
ALA with 2% lidocaine.  If 
required paracetamol, lidocaine, 
or bupivacaine. 
 ALA-PDT (fractionated) 15% vs ALA-PDT (single) 3% 
RR 4.85: 95%CI 1.34–17.53, p = 0.02 
 
Kessels 2017
25
 (Fractionated 
ALA-PDT) 
  No patient discontinued treatment because of pain. Pain score, mean NRS ± SD: MAL-PDT vs ALA-PDT 2-fold: 1
st
 
session; 2.25 ± 2.54 vs 1.88 ± 2.36, p = 0.369; 2
nd
 session; 
2.48 ± 2.57 vs 3.36 ± 2.57, p = 0.039.
25
 
16.4% in the ALA-PDT versus 5.8% in the MAL-PDT group 
reported the use of pain medication post-treatment. 
*Severe pain is defined as pain leading to break in treatment and/or the use of local analgesia. 
Abbreviations: MAL, methyl aminolaevulinate; ALA, 5-aminolaevulinic acid; PDT, photodynamic therapy; CI, confidence interval; RR, risk ratio; LA, local anaesthetic; VAS, visual analogue scale; FU, 5-fluorouracil; IMQ, imiquimod; AFL, Ablative Fractional 
Laser; Er:YAG, Erbium-doped Yttrium-Aluminium-Garnet; CO2-AFL, carbon dioxide Ablative Fractional Laser; NRS, numeric rating scale (score 0-10); SD: standard deviation 
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Figures 
Figure 1  PRISMA* flow chart of literature search strategy 
 
PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses; n, number 
Titles and abstracts 
screened after 
duplicates removed (n 
= 1353) 
Non-English 
references excluded 
(n = 163) 
References excluded 
by title and abstract (n 
= 1036) 
Papers included in 
quantitative synthesis 
(meta-analysis)  
(n = 19) 
Papers excluded from 
quantitative review 
with reasons for 
exclusion: see 
Appendix B (n = 136) 
References identified 
through database 
searching (n = 2,331) 
 
Full-text papers 
assessed for eligibility 
(n = 155) 
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Figure 2  Cosmetic outcome (excellent) patient (superficial and nodular): PDT versus 
cryosurgery (1 year) assessed by investigator 
 
PDT, photodynamic therapy; nBCC, nodular basal cell carcinoma; M-H, Mantel-Haenszel; CI, confidence 
interval; df, degrees of freedom. NB: Wang (2001) treated one lesion per patient (ALA-PDT); Basset-Seguin 
(2008) treated all lesions for each patient (MAL-PDT) 
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Figure 3  PDT vs surgical excision (nBCC): 3-month initial clearance 
 
PDT, photodynamic therapy; nBCC, nodular basal cell carcinoma; M-H, Mantel-Haenszel; CI, confidence 
interval; df, degrees of freedom. 
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Figure 4  PDT vs surgical excision (nBCC): 1-year sustained clearance 
 
PDT, photodynamic therapy; nBCC, nodular basal cell carcinoma; M-H, Mantel-Haenszel; CI, confidence 
interval; df, degrees of freedom. 
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Figure 5  PDT vs surgical excision (nBCC): Recurrence rate (>1 year) 
 
PDT, photodynamic therapy; nBCC, nodular basal cell carcinoma; M-H, Mantel-Haenszel; CI, confidence 
interval; df, degrees of freedom. 
 
Page 37 of 97 British Journal of Dermatology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
S1 
 
Conventional and combination topical photodynamic therapy for basal cell carcinoma:  
systematic review and meta-analysis 
Supporting Information 
Table S1 Search strategy 
Search no. Keywords CENTRAL MEDLINE 
and EMBASE 
PubMed 
1 
 
PubMed 
carcinoma, basal cell [MeSH Terms] 
OR basal cell carcinoma OR basal cell 
neoplasms OR basal cell cancer 
 
MEDLINE and EMBASE 
(basal ADJ0 cell ADJ0 carcinoma$1) 
OR (basal ADJ0 cell ADJ0 
neoplasm$1) OR (basal ADJ0 cell 
ADJ0 cancer$1) 
 
Cochrane 
(basal cell carcinoma*) OR (basal cell 
neoplasm*) OR (basal cell cancer*) 
1112 37778 
 
38167 
 
2 
 
PubMed 
photodynamic therapy [MeSH Terms] 
OR photodynamic therapy OR PDT) 
 
MEDLINE and EMBASE 
(photodynamic ADJ0 therapy) OR PDT 
 
Cochrane 
(photodynamic therapy) OR PDT 
1547 
 
41500 
 
21718 
3 
 
PubMed 
skin[MeSH Terms] OR cutaneous OR 
skin) 
 
MEDLINE and EMBASE 
Cutaneous OR skin 
 
Cochrane 
Cutaneous OR skin 
49701  1718477  778174 
4 1 AND 2 AND 3  
101(a) 
 
1572(b) 
 
658(c) 
 
a (101) + b (1572) + c(658) references combined in EndNote X7, with 
automatic and manual de-duplications yielding (1353) unique records 
BCC, basal cell carcinoma; PDT, photodynamic therapy; RCT, randomized controlled trial; nBCC, nodular basal 
cell carcinoma; sBCC, superficial basal cell carcinoma. 
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Table S2 Papers excluded from quantitative analysis 
 References Reason for exclusion from extraction 
1.  Alberdi, E. (2011) 
Photodiagnosis Photodyn Ther  
Conference abstract and no comparator arm 
2.  Allen, J. (2011) Photodiagnosis 
Photodyn Ther  
Conference abstract and no comparator arm 
3.  Al-Niaimi, F. (2015) J Cutan 
Aesthet Surg  
Outcomes not pertinent to this guideline 
4.  Annemans, L. (2008) Eur J 
Dermatol  
No comparator arm 
5.  Anolik, R. (2011) Lasers Surg 
Med  
Conference abstract and no comparator arm 
6.  Arits, A. (2015) Br J Dermatol  Letter no extractable data 
7.  Attili, S. K. (2012) 
Photodermatol Photoimmunol 
Photomed  
No comparator arm – case series review 
8.  Attili, SK (2009) Br J Dermatol No comparator arm 
9.  Baron, E. D. (2010) Lasers Surg 
Med  
Outcomes not pertinent to this guideline 
10.  Basset-Seguin, N. (2003) BAD 
abstract 
Conference abstract- Insufficient data to extract 
11.  Basset-Seguin, N. (2005) BAD 
abstract 
Conference abstract- Insufficient data to extract 
12.  Basset-Seguin, N. (2006) EADO 
abstract  
Conference abstract- Insufficient data to extract 
13.  Bath-Hextall, F. J. (2004) BMJ  Review 
14.  Bath-Hextall, F. J. (2007) 
Cochrane Database Syst Rev 
Review 
15.  Brown, S. B. (2009) BMJ (Online)  Review 
16.  Burón Álvarez, I. (2014) Piel  Unavailable 
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 References Reason for exclusion from extraction 
17.  Caekelbergh, K. (2009) J Drugs 
Dermatol  
Unavailable 
18.  Cai, M. (2009) J Clin Dermatol  Unavailable in English language 
19.  Campbell, S. M. (2007) J Environ 
Pathol Toxicol Oncol  
Unavailable 
20.  Campbell, S. M. (2008) Br J 
Dermatol  
Outcomes not pertinent to this guideline 
21.  Carija, A. (2016) Photodiagnosis 
Photodyn Ther 
Not randomised clinical trial 
22.  Chia, H. Y. (2015) Indian J 
Dermatol Venereol Leprol  
Case series 
23.  Christensen, E. (2009) J Eur 
Acad Dermatol Venereol  
No comparator arm 
24.  Christensen, E. (2011) Acta 
Derm Venereol  
Outcomes not pertinent to this guideline 
25.  Christensen, E. (2011) J Skin 
Cancer  
No comparator arm 
26.  Christensen, E. (2012) Br J 
Dermatol  
No comparator arm 
27.  Clark, C. 2003 (Photodermatol 
Photoimmunol Photomed) 
Not randomised clinical trial 
28.  Clayton, T.H 2006 (Euro J Derm) Outcomes not pertinent to this guideline 
29.  Collier, N. J. (2015) Lasers Med 
Sci  
No comparator arm 
30.  Cosgarea, R. (2013) J Eur Acad 
Dermatol Venereol  
Not randomised clinical trial 
31.  Cottrell, W. J. (2008) Clin Cancer 
Res  
Outcomes not pertinent to this guideline 
32.  Curnow, A. (2010) Br J Dermatol  No comparator arm 
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 References Reason for exclusion from extraction 
33.  de Haas, E. R. (2008) Acta Derm 
Venereol  
Outcomes not pertinent to this guideline 
34.  de Haas, E. R. (2008) J Eur Acad 
Dermatol Venereol  
No comparator arm 
35.  Desai, S. (2010) Lasers Surg Med  No comparator arm 
36.  Fai, D. (2009) G Ital Dermatol 
Venereol  
No comparator arm 
37.  Fantini, F. (2011) J Eur Acad 
Dermatol Venereol  
No comparator arm 
38.  Farhadi, M. (2010) J Drugs 
Dermatol  
Unavailable 
39.  Fernandez-Guarino, M. (2014) J 
Skin Cancer  
No comparator arm 
40.  Fiechter, S. (2012) Dermatology  No comparator arm 
41.  Fink-Puches, R (1998) Arch 
Dermatol 
No comparator arm 
42.  Gilchrest, B. A. (2009) Dermatol 
Surg  
Case series 
43.  Gracia-Cazana, T. (2017) 
Photodiagnosis Photodyn Ther 
No comparator arm 
44.  Griskjans, Z. (2013) 
Stomatologija  
No comparator arm 
45.  Grose, D. (2014) Dermatol Surg  Letter 
46.  Haak, C. S. (2013) Lasers Surg 
Med  
Abstract 
47.  Haedersdal, M. (2012) Lasers 
Med Sci  
Case series 
48.  Halldin, C.B (2011) Acta Derm 
Venereol 
Not randomised clinical trial 
49.  Haller, J.C (2000) Br J Dermatol No comparator arm 
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 References Reason for exclusion from extraction 
50.  Hamdoon, Z. (2011) Br J Oral 
Maxillofac Surg  
Abstract- no comparator arm 
51.  Hamdoon, Z. (2011) 
Photodiagnosis Photodyn Ther  
Abstract- no comparator arm 
52.  Holmes, M V (2004) Br J 
Dermatol 
Outcomes not pertinent to this guideline 
53.  Horn, M (2003) Br J Dermatol Not randomised clinical trial 
54.  Itoh, (2000) Y J Dermatol No comparator arm 
55.  Kauvar, A. N. B. (2015) Dermatol 
Surg  
Review 
56.  Kessels, J.P. (2017) Acta Derm 
Venereol 
Not randomised clinical trial 
57.  Kuijpers, D.I. (2006) J Drugs 
Dermatol 
No comparator arm besides PDT 
58.  Kulakov, E. (2015) J Am Acad 
Dermatol  
Meeting abstract – no comparator arm 
59.  Lecluse, L. L. (2015) Br J 
Dermatol  
Letter - discussing Arits (2013) Lancet Oncol. 
which is included 
60.  Li, Q. (2011) Photomed Laser 
Surg  
Case series No comparator arm  
61.  Lindberg-Larsen, R. (2012) Acta 
Derm Venereol  
No comparator arm 
62.  Lippert, J. (2013) Dermatol Surg  Not randomised clinical trial 
63.  Loncaster, J. (2009) Clin Oncol 
(R Coll Radiol)  
No comparator arm – review of cases 
64.  Longo, C. (2012) Dermatology  Not an end point evaluated in these guidelines 
65.  Lu, Y. G. (2014) Photodiagnosis 
Photodyn Ther  
No comparator arm 
66.  Malik, Z. (2015) Photonics 
Lasers Med  
Review 
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 References Reason for exclusion from extraction 
67.  Mangano, A. (2009) Br J 
Dermatol  
No comparator arm 
68.  Maresso, K. C. (2015) CA Cancer 
J Clin  
Review 
69.  Meijnders, P.J.N (1996) Lasers 
Med Sci 
Not randomised clinical trial 
70.  Metterle, L. (2015) Curr Probl 
Cancer  
Review 
71.  Morton, C. A. (2013) J Eur Acad 
Dermatol Venereol  
PDT guidelines - review 
72.  Mosterd, K. (2013) J Eur Acad 
Dermatol Venereol  
No comparator arm 
73.  Mougel, F. (2009) Dermatology  No comparator arm 
74.  Naidenov, N (2004) Acta 
Dermatovenrol Croat 
No comparator arm 
75.  Neves, D. R. (2010) An Bras 
Dermatol  
Case report 
76.  Nijsten, T. (2015) Br J Dermatol  Letter – no extractable data 
77.  Oh, C. C. (2014) Br J Dermatol  Conference abstract – no comparator arm 
78.  Ong, M. W. S. (2015) J Am Acad 
Dermatol  
Conference abstract –no comparator arm 
79.  Pauwels, C. (2011) J Eur Acad 
Dermatol Venereol  
No comparator arm 
80.  Payne, K. F. B. (2013) Br J Oral 
Maxillofac Surg  
Conference abstract – no comparator arm 
81.  Pereyra-Rodriguez, J. J. (2009) 
Indian J Dermatol Venereol 
Leprol  
Case study  
82.  Puccioni, M. (2009) Ophthal 
Plast Reconstr Surg  
No comparator arm 
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 References Reason for exclusion from extraction 
83.  Pye, A. (2008) J Cancer Res Clin 
Oncol  
Outcomes not pertinent to this guideline 
84.  Ramirez, D. P. (2014) 
Photodiagnosis Photodyn Ther  
No comparator arm  
85.  Reddy, K. K. (2010) J Drugs 
Dermatol  
Unavailable 
86.  Requena, C. (2012) Int J 
Dermatol  
Case study 
87.  Rhodes, L. E. (2007) BAD 
conference abstract 
Conference abstract- Insufficient data to extract 
88.  Rhodes, L. E. (2007) EADV 
conference abstract 
Conference abstract- Insufficient data to extract 
89.  Rkein, A. M. (2014) Dermatol 
Clin  
Review 
90.  Roberts, G. (2015) Br J Dermat  Conference abstract 
91.  Rodriguez-Prieto, M. A. (2012) J 
Am Acad Dermatol.  
No comparator arm 
92.  Roozeboom, M. H. (2012) Br J 
Dermatol.  
Review 
93.  Roozeboom, M. H. (2015) J Am 
Acad Dermatol.  
Case controlled study 
94.  Ruiz, E. S. (2015) J Drugs 
Dermatol.  
Review 
95.  Saager, R. B. (2011) Lasers Surg 
Med  
No comparator arm and outcomes not 
pertinent to this guideline 
96.  Salavastru, C. (2014) J Am Acad 
Dermatol  
Conference abstract - no comparator arm 
97.  Samy, N. A. (2015) Lasers Med 
Sci  
Outcomes not pertinent to this guideline  
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 References Reason for exclusion from extraction 
98.  Sandberg, C. (2008) Br J 
Dermatol  
Outcomes not pertinent to this guideline 
99.  Schweiger, E. S. (2010) J Drugs 
Dermatol; 9: 167–8  
Unable to access this reference: case report  
100. Sebaratnam, D. F. (2010) 
Australas J Dermatol  
Conference abstract, full paper Sebaratnam 
(2011) which has been included 
101. Sebaratnam, D. F. (2011) J Eur 
Acad Dermatol Venereol  
Insufficient data to extract 
102. Segura, S. (2011) J Eur Acad 
Dermatol Venereol  
No comparator arm 
103. Serra-Guillén, C. (2012) Actas 
Dermosifiliogr  
Review 
104. Shokrollahi, K. (2009) Cases J  Case report 
105. Shokrollahi, K. (2014) Ann Plast 
Surg  
No comparator arm 
106. Shumack, S. (2009) Australas J 
Dermatol  
Conference abstract – no extractable data 
107. Sidoroff, A. (2010) 
Photodiagnosis Photodyn Ther  
Review 
108. Smucler, R. (2011) Lasers Surg 
Med.  
Conference abstract- Insufficient data to extract 
109. Smucler, R. (2012) Photomed 
Laser Surg  
Not randomised clinical trial 
110. Soler, A.M. (2000) 
Photodiagnosis Photodyn Ther 
No comparator arm besides PDT 
111. Soler, A.M. (2000) Brit J 
Dermatol  
Not randomised clinical trial 
112. Soler, A.M. (1999) Acta Derm 
Venereol  
Not randomised clinical trial 
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 References Reason for exclusion from extraction 
113. Sotiriou, E. (2013) J Dtsch 
Dermatol Ges; 22–3 
Conference abstract - no comparator arm 
114. Sotiriou, E. (2013) J Dtsch 
Dermatol Ges; 110  
Conference abstract – insufficient data to 
extract 
115. Souza, C. S. (2009) 
Photodiagnosis Photodyn Ther  
No comparator arm 
116. Spada, J. (2012) J Am Acad 
Dermatol  
Conference abstract – case study 
117. Star, W.M. (2006) Acta Derm 
Venereol 
Not randomised clinical trial 
118. Sunar, U. (2013) Lasers Surg 
Med  
Conference abstract – outcomes not pertinent 
to this guideline 
119. Sunar, U. (2013) Biomed Opt 
Express  
Outcomes not pertinent to this guideline 
120. Surrenti, T. (2007) Eur J 
Dermatol  
From abstract no comparator arm 
121. Szeimies, R. M. (2007) Dermatol 
Clin  
Review 
122. Taborda, V (2016) J Eur Acad 
Dermatol 
Not randomised clinical trial 
123. Tehranchinia, Z. (2013) Indian J 
Dermatol  
No comparator arm 
124. Themstrup, L. (2014) 
Photodiagnosis Photodyn Ther  
No comparator arm 
125. Thissen, M.R. (2000) Brit J 
Dermatol  
No comparator arm 
126. Tierney, E. (2010) Lasers Surg 
Med; 7  
No comparator arm 
127. Tierney, E. P. (2010) Lasers Surg 
Med; 37  
Conference abstract - no comparator arm. case 
series 
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 References Reason for exclusion from extraction 
128. Toll, A. (2008) Dermatol Surg  Case report 
129. Torres, T. (2010) J Am Acad 
Dermatol  
Conference abstract – no comparator arm. Case 
study 
130. Valentine, R. (2011) Lasers Med 
Sci  
Conference abstract – insufficient data to 
extract 
131. Venturini, M. (2013) Br J 
Dermatol  
No comparator arm 
132. Vinviullo, C (2005) Brit J 
Dermatol 
No comparator arm 
133. Wang, K. K. (2009) Lasers Surg 
Med  
Outcomes not pertinent to this guideline 
134. Wang, Y. (2009) Chin Ger J Clin 
Oncol  
No comparator arm  
135. Whitaker, I. S. (2007) Ann Plast 
Surg 
No comparator arm 
136. Zeitouni, N.C. (2014) Dermatol 
Surg 
No comparator arm besides PDT 
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Table S3 Cochrane risk of bias 
Publication Outcome 
BIAS 
Overall Selection  Performance  Attrition  Detection Outcome Other  
Wang Br J 
Dermatol. 2001 
Recurrence rate (> 1 
year) 
High risk Low risk High risk Low risk Low risk Low risk 
Low 
risk 
Wang Br J 
Dermatol. 2001 
Cosmetic outcome Low risk Low risk Low risk Low risk Low risk Low risk 
Low 
risk 
Wang Br J 
Dermatol. 2001 
Severe pain High risk Low risk High risk Low risk Low risk Low risk 
Low 
risk 
Rhodes. Arch 
Dermatol. 2004 
Initial clearance of 
BCC (3 months) 
High risk Low risk High risk Low risk Low risk Low risk 
Low 
risk 
Rhodes. Arch 
Dermatol. 2004 
Sustained clearance 
of BCC (1 year) 
High risk Low risk High risk Low risk Low risk Low risk 
Low 
risk 
Rhodes. Arch 
Dermatol. 2004 
Recurrence rate (> 1 
year) 
High risk Low risk High risk Low risk Low risk Low risk 
Low 
risk 
Rhodes. Arch 
Dermatol. 2004 
Treatment 
tolerability 
High risk Low risk High risk Low risk Low risk Low risk 
Low 
risk 
Rhodes. Arch 
Dermatol. 2004 
Cosmetic outcome High risk Low risk High risk Low risk Low risk Low risk 
Low 
risk 
Rhodes Arch 
Dermatol, 2007 
Sustained clearance 
of BCC (5 years)  
High risk Low risk High risk Low risk Low risk Low risk 
Low 
risk 
Rhodes Arch 
Dermatol, 2007 
Cosmetic outcome High risk Low risk High risk Low risk Low risk Low risk 
Low 
risk 
Rhodes Arch 
Dermatol, 2007 
Severe pain High risk Low risk High risk Low risk Low risk Low risk 
Low 
risk 
de Haas J. Invest. 
Dermatol. 2006 
Sustained clearance 
of BCC (1 year) 
High risk Low risk High risk Low risk Low risk Low risk 
Low 
risk 
de Haas. J. Invest 
Dermatol. 2006 
Severe pain High risk Low risk High risk Low risk Low risk Low risk 
Low 
risk 
de Vijlder. Acta. 
Derm. Venereol. 
2012 
Sustained clearance 
of BCC (5 years)  
High risk Low risk High risk Low risk Low risk Low risk 
Low 
risk 
Kessels Br J 
Dermatol. 2017 
Initial clearance of 
BCC (3 months) 
High risk Low risk High risk Low risk Low risk Low risk 
Low 
risk 
Kessels Br J 
Dermatol. 2017 
Sustained clearance 
of BCC (1 year) 
High risk Low risk High risk Low risk Low risk Low risk 
Low 
risk 
Kessels Br J 
Dermatol. 2017 
Cosmetic outcome High risk Low risk High risk Low risk Low risk Low risk 
Low 
risk 
L. Berroeta Br J 
Dermatol. 2007 
Sustained clearance 
of BCC (1 year) 
High risk Low risk High risk Low risk Low risk Low risk 
Low 
risk 
L. Berroeta Br J 
Dermatol. 2007 
Treatment 
tolerability 
High risk Low risk High risk Low risk Low risk Low risk 
Low 
risk 
Smucler. Lasers 
Surg. Med. 2008 
Initial clearance of 
BCC (3 months) 
Very High 
risk 
High risk High risk Low risk Low risk Low risk 
Low 
risk 
Smucler. Lasers 
Surg. Med. 2008 
Sustained clearance 
of BCC (1 year) 
Very High 
risk 
High risk High risk High risk Low risk Low risk 
Low 
risk 
Smucler Lasers 
Surg. Med. 2008 
Cosmetic outcome 
Very High 
risk 
High risk High risk High risk Low risk Low risk 
Low 
risk 
Szeimies J Eur 
Acad Dermatol 
Venereol. 2008 
Initial clearance of 
BCC (3 months) 
High risk Low risk High risk Low risk Low risk Low risk 
Low 
risk 
Szeimies J Eur 
Acad Dermatol 
Venereol. 2008 
Sustained clearance 
of BCC (1 year) 
High risk Low risk High risk Low risk Low risk Low risk 
Low 
risk 
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Szeimies J Eur 
Acad Dermatol 
Venereol. 2008 
Cosmetic outcome High risk Low risk High risk Low risk Low risk Low risk 
Low 
risk 
Mosterd Br J 
Dermatol. 2008 
Initial clearance of 
BCC (3 months) 
High risk Low risk High risk Low risk Low risk Low risk 
Low 
risk 
Mosterd Br J 
Dermatol. 2008 
Sustained clearance 
of BCC (1 year) 
High risk Low risk High risk Low risk Low risk Low risk 
Low 
risk 
Roozeboom, J. 
Am Acad 
Dermatol. 2013 
Sustained clearance 
of BCC (5 years)  
High risk Low risk High risk Low risk Low risk Low risk 
Low 
risk 
Roozeboom, J. 
Am Acad 
Dermatol. 2013 
Recurrence rate (> 1 
year) 
High risk Low risk High risk Low risk Low risk Low risk 
Low 
risk 
Basset-Seguin, 
Eur. J. Dermatol. 
2008 
Initial clearance of 
BCC (3 months) 
High risk Low risk High risk Low risk Low risk Low risk 
Low 
risk 
Basset-Seguin, 
Eur. J. Dermatol. 
2008 
Sustained clearance 
of BCC (1 year) 
High risk Low risk High risk Low risk Low risk Low risk 
Low 
risk 
Basset-Seguin. 
Eur. J. Dermatol. 
2008 
Sustained clearance 
of BCC (5 years)  
High risk Low risk High risk Low risk Low risk Low risk 
Low 
risk 
Basset-Seguin, 
Eur. J. Dermatol. 
2008 
Recurrence rate (> 1 
year) 
High risk Low risk High risk Low risk Low risk Low risk 
Low 
risk 
Basset-Seguin, 
Eur. J. Dermatol. 
2008 
Cosmetic outcome 
Very High 
risk 
High risk High risk Low risk Low risk Low risk 
Low 
risk 
Basset-Seguin, 
Eur. J. Dermatol. 
2008 
Treatment 
tolerability 
High risk Low risk High risk Low risk Low risk Low risk 
Low 
risk 
Basset-Seguin, 
Eur. J. Dermatol. 
2008 
Severe pain High risk Low risk High risk Low risk Low risk Low risk 
Low 
risk 
Foley, Int. J. 
Dermatol. 2009 
Initial clearance of 
BCC (3 months) 
High risk Low risk Low risk Low risk Low risk High risk 
Low 
risk 
Foley, Int. J. 
Dermatol. 2009 
Cosmetic outcome 
Very High 
risk 
Low risk Low risk 
Very 
High risk 
Low risk High risk 
Low 
risk 
Foley, Int. J. 
Dermatol. 2009 
Treatment 
tolerability 
Low risk Low risk Low risk Low risk Low risk Low risk 
Low 
risk 
Foley, Int. J. 
Dermatol. 2009 
Severe pain Low risk Low risk Low risk Low risk Low risk Low risk 
Low 
risk 
Osiecka, Med. 
Sci. Monit. 2012 
Recurrence rate (> 1 
year) 
Very High 
risk 
Low risk High risk Low risk Low risk High risk 
Low 
risk 
Arits, Lancet 
Oncol. 2013 
Initial clearance of 
BCC (3 months) 
High risk Low risk High risk Low risk Low risk Low risk 
Low 
risk 
Arits, Lancet 
Oncol. 2013 
Sustained clearance 
of BCC (1 year) 
High risk Low risk High risk Low risk Low risk Low risk 
Low 
risk 
Arits, Lancet 
Oncol. 2013 
Treatment 
tolerability 
High risk Low risk High risk Low risk Low risk Low risk 
Low 
risk 
Arits, Lancet 
Oncol. 2013 
Severe pain High risk Low risk High risk Low risk Low risk Low risk 
Low 
risk 
Arits, Lancet 
Oncol. 2013 
Cosmetic outcome High risk Low risk High risk Low risk Low risk Low risk 
Low 
risk 
Jansen, J Invest 
Dermatol. 2017. 
Sustained clearance 
of BCC (5 years) 
High risk Low risk High risk Low risk Low risk Low risk 
Low 
risk 
Haak, Br. J. 
Dermatol. 2015 
Initial clearance of 
BCC (3 months) 
Low risk Low risk Low risk Low risk Low risk Low risk 
Low 
risk 
Haak, Br. J. 
Dermatol. 2015 
Sustained clearance 
of BCC (1 year) 
Low risk Low risk Low risk Low risk Low risk Low risk 
Low 
risk 
Haak, Br. J. 
Dermatol. 2015 
Sustained clearance 
of BCC (1 year) 
Low risk Low risk Low risk Low risk Low risk Low risk 
Low 
risk 
Haak, Br. J. 
Dermatol. 2015 
Cosmetic outcome Low risk Low risk Low risk Low risk Low risk Low risk 
Low 
risk 
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Haak, Br. J. 
Dermatol. 2015 
Other adverse effects Low risk Low risk Low risk Low risk Low risk Low risk 
Low 
risk 
Choi, JEADV. 
2016 
Initial clearance of 
BCC (3 months) 
Low risk Low risk Low risk Low risk Low risk Low risk 
Low 
risk 
Choi, JEADV. 
2016 
Sustained clearance 
of BCC (1 year) 
Low risk Low risk Low risk Low risk Low risk Low risk 
Low 
risk 
Choi, JEADV. 
2016 
Recurrence rate (> 1 
year) 
Low risk Low risk Low risk Low risk Low risk Low risk 
Low 
risk 
Choi, JEADV. 
2016 
Cosmetic outcome Low risk Low risk Low risk Low risk Low risk Low risk 
Low 
risk 
Choi, JEADV. 
2016 
Other adverse effects Low risk Low risk Low risk Low risk Low risk Low risk 
Low 
risk 
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Table S4 GRADE evidence 
 
PDT vs placebo-PDT 
 
Quality assessment 
 
No of patients 
 
Effect 
 
 
Quality 
 
 
Importance 
No of 
studies 
Design 
Risk of 
bias 
Inconsistency Indirectness Imprecision 
Other 
considerations 
PDT 
Placebo- 
PDT 
Relative 
(95% CI) 
Absolute 
Clearance of treated BCC (3 months initial lesion clearance) lesion: MAL-PDT vs placebo 
1 randomised 
trials 
serious1 no serious 
inconsistency 
no serious 
indirectness 
no serious 
imprecision 
none 55/75 
(73.3%) 
26.7% RR 2.75 (1.84 
to 4.1) 
467 more per 1000 (from 
224 more to 828 more) 
⊕⊕⊕Ο 
MODERATE 
CRITICAL 
Severe pain (leading to break in treatment/use of local analgesia) patient: MAL-PDT vs placebo 
1 randomised 
trials 
serious1 2 no serious 
indirectness 
2 none 0/66 
(0%) 
0% not pooled not pooled 2 CRITICAL 
Cosmetic outcome (excellent or good) lesion: MAL-PDT vs placebo 
1 randomised 
trials 
very 
serious1 
no serious 
inconsistency 
no serious 
indirectness 
no serious 
imprecision 
none 42/75 
(56%) 
18.7% RR 3 (1.8 to 
5.01) 
374 more per 1000 (from 
150 more to 750 more) 
⊕⊕ΟΟ 
LOW 
IMPORTANT
Treatment tolerability - low or manageable pain, patient: MAL-PDT vs placebo 
1 randomised 
trials 
serious1 no serious 
inconsistency 
no serious 
indirectness 
serious3 none 60/66 
(90.9%) 
66.2% RR 1.37 (1.14 
to 1.66) 
245 more per 1000 (from 
93 more to 437 more) 
⊕⊕ΟΟ 
LOW 
IMPORTANT
1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias 
2 Unable to assess inconsistency, imprecision or outcome due to lack of events in either arm 
3 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs 
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PDT vs cryosurgery 
 
Quality assessment 
 
No of patients 
 
Effect 
 
 
Quality 
 
 
Importance 
No of 
studies 
Design Risk of bias Inconsistency Indirectness Imprecision 
Other 
considerations 
PDT Cryosurgery
Relative 
(95% CI) 
Absolute 
Clearance of treated BCC (3 months initial lesion clearance) lesion: PDT vs cryosurgery 
1 randomised 
trials 
serious1 no serious 
inconsistency 
no serious 
indirectness 
no serious 
imprecision2 
none 56/62 
(90.3%) 
89.7% RR 1.01 
(0.89 to 1.14) 
9 more per 1000 (from 
99 fewer to 126 more) 
⊕⊕⊕Ο 
MODERATE 
CRITICAL 
Sustained clearance of treated BCC (1 year) patient: MAL-PDT vs Cryosurgery 
1 randomised 
trials 
serious1 no serious 
inconsistency 
no serious 
indirectness 
no serious 
imprecision2 
none 51/56 
(91.1%) 
92.3% RR 0.99 
(0.88 to 1.11) 
9 fewer per 1000 (from 
111 fewer to 102 more) 
⊕⊕⊕Ο 
MODERATE 
CRITICAL 
Sustained clearance of treated BCC (5 years) patient: MAL-PDT vs Cryosurgery 
1 randomised 
trials 
serious1 no serious 
inconsistency 
no serious 
indirectness 
serious3 none 32/56 
(57.1%) 
78.9% RR 0.72 
(0.55 to 0.95) 
221 fewer per 1000 
(from 39 fewer to 355 
fewer) 
⊕⊕ΟΟ 
LOW 
CRITICAL 
Recurrence rate (1 year) patient (superficial): PDT vs cryosurgery 
1 randomised 
trials 
serious1 no serious 
inconsistency 
no serious 
indirectness 
serious3 none 8/22 
(36.4%) 
5.9% RR 6.18 
(0.85 to 
44.78) 
306 more per 1000 
(from 9 fewer to 1000 
more) 
⊕⊕ΟΟ 
LOW 
CRITICAL 
Recurrence rate (1 year) patient (nodular): PDT vs cryosurgery 
1 randomised 
trials 
serious1 no serious 
inconsistency 
no serious 
indirectness 
very serious3 none 3/25 
(12%) 
20.8% RR 0.58 
(0.15 to 2.15) 
87 fewer per 1000 
(from 177 fewer to 239 
more) 
⊕ΟΟΟ 
VERY LOW 
CRITICAL 
Recurrence rate (>1 year <2 years) patient: PDT vs cryosurgery 
1 randomised 
trials 
serious1 no serious 
inconsistency 
no serious 
indirectness 
very serious3 none 7/51 
(13.7%) 
6.3% RR 2.2 (0.6 
to 8.01) 
76 more per 1000 
(from 25 fewer to 442 
more) 
⊕ΟΟΟ 
VERY LOW 
CRITICAL 
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Recurrence rate (>1 year <3 years) patient: PDT vs cryosurgery 
1 randomised 
trials 
serious1 no serious 
inconsistency 
no serious 
indirectness 
serious3 none 11/51 
(21.6%) 
6.3% RR 3.45 
(1.02 to 
11.62) 
154 more per 1000 
(from 1 more to 669 
more) 
⊕⊕ΟΟ 
LOW 
CRITICAL 
Recurrence rate (>1 year <4 years) patient: PDT vs cryosurgery 
1 randomised 
trials 
very serious1 no serious 
inconsistency 
no serious 
indirectness 
serious3 none 11/51 
(21.6%) 
6.3% RR 3.45 
(1.02 to 
11.62) 
154 more per 1000 
(from 1 more to 669 
more) 
⊕ΟΟΟ 
VERY LOW 
CRITICAL 
Recurrence rate (>1 year <5 years) patient: PDT vs cryosurgery 
1 randomised 
trials 
very serious1 no serious 
inconsistency 
no serious 
indirectness 
serious3 none 11/51 
(21.6%) 
8.3% RR 2.59 
(0.88 to 7.58) 
132 more per 1000 
(from 10 fewer to 546 
more) 
⊕ΟΟΟ 
VERY LOW 
CRITICAL 
Severe pain (leading to break in treatment/use of local analgesia) patient: PDT vs cryosurgery 
2 randomised 
trials 
serious1 no serious 
inconsistency 
no serious 
indirectness 
very serious3 none 4/109 
(3.7%) 
0.9% RR 2.74 
(0.44 to 
17.06) 
16 more per 1000 
(from 5 fewer to 145 
more) 
⊕ΟΟΟ 
VERY LOW 
CRITICAL 
Cosmetic outcome (excellent) patient: PDT vs cryosurgery (3 months) assessed by investigator 
1 randomised 
trials 
very serious1 no serious 
inconsistency 
no serious 
indirectness 
no serious 
imprecision 
none 17/62 
(27.4%) 
3.5% RR 7.95 
(1.92 to 
32.92) 
243 more per 1000 
(from 32 more to 1000 
more) 
⊕⊕ΟΟ 
LOW 
IMPORTANT 
Cosmetic outcome (excellent) patient: PDT vs cryosurgery (3 months) assessed by patient 
1 randomised 
trials 
very serious1 no serious 
inconsistency 
no serious 
indirectness 
serious3 none 25/62 
(40.3%) 
19% RR 2.13 
(1.15 to 3.92) 
215 more per 1000 
(from 28 more to 555 
more) 
⊕ΟΟΟ 
VERY LOW 
IMPORTANT 
Cosmetic outcome (excellent) patient: PDT vs cryosurgery (1 year) assessed by investigator 
2 randomised 
trials 
very serious1 no serious 
inconsistency 
no serious 
indirectness 
no serious 
imprecision 
none 41/109 
(37.6%) 
9.7% RR 3.73 
(1.96 to 7.07) 
265 more per 1000 
(from 93 more to 589 
more) 
⊕⊕ΟΟ 
LOW 
IMPORTANT 
Cosmetic outcome (excellent) patient: PDT vs cryosurgery (1 year) assessed by patient 
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1 randomised 
trials 
very serious1 no serious 
inconsistency 
no serious 
indirectness 
serious3 none 22/62 
(35.5%) 
24.1% RR 1.47 
(0.83 to 2.59) 
113 more per 1000 
(from 41 fewer to 383 
more) 
⊕ΟΟΟ 
VERY LOW 
IMPORTANT 
Cosmetic outcome (excellent) patient: PDT vs cryosurgery (2 years) assessed by investigator 
1 randomised 
trials 
very serious1 no serious 
inconsistency 
no serious 
indirectness 
no serious 
imprecision 
none 25/62 
(40.3%) 
6.9% RR 5.85 
(2.17 to 
15.78) 
335 more per 1000 
(from 81 more to 1000 
more) 
⊕⊕ΟΟ 
LOW 
IMPORTANT 
Cosmetic outcome (excellent) patient: PDT vs cryosurgery (2 years) assessed by patient 
1 randomised 
trials 
very serious1 no serious 
inconsistency 
no serious 
indirectness 
serious3 none 23/62 
(37.1%) 
25.9% RR 1.43 
(0.83 to 2.47) 
111 more per 1000 
(from 44 fewer to 381 
more) 
⊕ΟΟΟ 
VERY LOW 
IMPORTANT 
Cosmetic outcome (excellent) patient: PDT vs cryosurgery (3 years) assessed by investigator 
1 randomised 
trials 
very serious1 no serious 
inconsistency 
no serious 
indirectness 
no serious 
imprecision 
none 19/62 
(30.6%) 
8.6% RR 3.55 
(1.42 to 8.9) 
219 more per 1000 
(from 36 more to 679 
more) 
⊕⊕ΟΟ 
LOW 
IMPORTANT 
Cosmetic outcome (excellent) patient: PDT vs cryosurgery (4 years) assessed by investigator 
1 randomised 
trials 
very serious1 no serious 
inconsistency 
no serious 
indirectness 
no serious 
imprecision 
none 19/62 
(30.6%) 
8.6% RR 3.55 
(1.42 to 8.9) 
219 more per 1000 
(from 36 more to 679 
more) 
⊕⊕ΟΟ 
LOW 
IMPORTANT 
Cosmetic outcome (excellent) patient: PDT vs cryosurgery (5 years) assessed by investigator 
1 randomised 
trials 
very serious1 no serious 
inconsistency 
no serious 
indirectness 
no serious 
imprecision 
none 19/62 
(30.6%) 
12.1% RR 2.54 
(1.15 to 5.59) 
186 more per 1000 
(from 18 more to 555 
more) 
⊕⊕ΟΟ 
LOW 
IMPORTANT 
Treatment tolerability - low or manageable pain PDT vs cryosurgery 
1 randomised 
trials 
no serious 
risk of bias 
no serious 
inconsistency 
no serious 
indirectness 
serious3 none 46/62 
(74.2%) 
72.4% RR 1.02 
(0.83 to 1.27) 
14 more per 1000 
(from 123 fewer to 195 
more) 
⊕⊕⊕Ο 
MODERATE 
IMPORTANT 
1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias 
2 No clinical important difference - between MIDs 
3 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs 
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PDT vs surgical excision 
 
Quality assessment 
 
No of patients 
 
Effect 
 
 
Quality 
 
 
Importance 
No of 
studies 
Design 
Risk of 
bias 
Inconsistency Indirectness Imprecision 
Other 
considerations 
PDT Surgical
Relative 
(95% CI) 
Absolute 
Clearance of treated sBCC (3 months initial lesion clearance) lesion: PDT vs surgical excision 
1 randomised 
trials 
serious1 no serious 
inconsistency 
no serious 
indirectness 
no serious 
imprecision2 
none 118/135 
(87.4%) 
88.6% RR 0.99 (0.9 
to 1.08) 
9 fewer per 1000 (from 89 
fewer to 71 more) 
⊕⊕⊕Ο 
MODERATE
CRITICAL 
Clearance of treated nBCC (3 months initial lesion clearance) lesion: PDT vs surgical excision 
1 randomised 
trials 
serious1 no serious 
inconsistency 
no serious 
indirectness 
no serious 
imprecision2 
none 48/53 
(90.6%) 
98.1% RR 0.92 (0.84 
to 1.02) 
78 fewer per 1000 (from 
157 fewer to 20 more) 
⊕⊕⊕Ο 
MODERATE
CRITICAL 
Sustained clearance of treated sBCC (1 year) lesion: PDT vs surgical excision 
1 randomised 
trials 
serious1 no serious 
inconsistency 
no serious 
indirectness 
no serious 
imprecision2 
none 107/118 
(90.7%) 
100% RR 0.91 (0.85 
to 0.96) 
90 fewer per 1000 (from 
40 fewer to 150 fewer) 
⊕⊕⊕Ο 
MODERATE
CRITICAL 
Sustained clearance of treated nBCC (1 year) lesion: PDT vs surgical excision 
2 randomised 
trials 
serious1 no serious 
inconsistency 
no serious 
indirectness 
no serious 
imprecision2 
none 57/69 
(82.6%) 
88.5% RR 0.9 (0.8 to 
1.01) 
89 fewer per 1000 (from 
177 fewer to 9 more) 
⊕⊕⊕Ο 
MODERATE
CRITICAL 
Sustained clearance of treated BCC (5 years) patient: PDT vs surgical excision 
1 randomised 
trials 
very 
serious1 
no serious 
inconsistency 
no serious 
indirectness 
serious3 none 31/52 
(59.6%) 
71.4% RR 0.83 (0.63 
to 1.11) 
121 fewer per 1000 (from 
264 fewer to 79 more) 
⊕ΟΟΟ 
VERY LOW 
CRITICAL 
Recurrence rate (>1 year <2 years) lesion: PDT vs surgical excision 
1 randomised 
trials 
serious1 no serious 
inconsistency 
no serious 
indirectness 
very serious3 none 3/44 
(6.8%) 
2% RR 3.41 (0.37 
to 31.6) 
48 more per 1000 (from 
13 fewer to 612 more) 
⊕ΟΟΟ 
VERY LOW 
CRITICAL 
Recurrence rate (>1 year <5 years) lesion: PDT vs surgical excision 
1 randomised very no serious no serious very serious3 none 5/49 3.9% RR 2.65 (0.54 64 more per 1000 (from ⊕ΟΟΟ CRITICAL 
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 trials serious1 inconsistency indirectness   (10.2%)  to 13.05) 18 fewer to 470 more) VERY LOW  
Cosmetic outcome (excellent or good) patient: PDT vs surgical excision (3 months) assessed by investigator 
1 randomised 
trials 
serious1 no serious 
inconsistency 
no serious 
indirectness 
no serious 
imprecision 
none 36/50 
(72%) 
31.9% RR 2.26 (1.44 
to 3.54) 
402 more per 1000 (from 
140 more to 810 more) 
⊕⊕⊕Ο 
MODERATE
IMPORTANT
Cosmetic outcome (excellent or good) patient: PDT vs surgical excision (3 months) assessed by patient 
1 randomised 
trials 
serious1 no serious 
inconsistency 
no serious 
indirectness 
no serious 
imprecision2 
none 39/50 
(78%) 
78.7% RR 0.99 (0.8 
to 1.22) 
8 fewer per 1000 (from 
157 fewer to 173 more) 
⊕⊕⊕Ο 
MODERATE
IMPORTANT
Cosmetic outcome (excellent or good) sBCC patient: PDT vs surgical excision (1 year) assessed by investigator 
1 randomised 
trials 
serious1 no serious 
inconsistency 
no serious 
indirectness 
no serious 
imprecision 
none 77/100 
(77%) 
45.8% RR 1.68 (1.32 
to 2.14) 
311 more per 1000 (from 
147 more to 522 more) 
⊕⊕⊕Ο 
MODERATE
IMPORTANT
Cosmetic outcome (excellent or good) nBCC patient: PDT vs surgical excision (1 year) assessed by investigator 
1 randomised 
trials 
serious1 no serious 
inconsistency 
no serious 
indirectness 
serious3 none 33/50 
(66%) 
36.2% RR 1.82 (1.19 
to 2.8) 
297 more per 1000 (from 
69 more to 652 more) 
⊕⊕ΟΟ 
LOW 
IMPORTANT
Cosmetic outcome (excellent or good) nBCC patient: PDT vs surgical excision (1 year) assessed by patient 
1 randomised 
trials 
serious1 no serious 
inconsistency 
no serious 
indirectness 
serious3 none 41/50 
(82%) 
76.6% RR 1.07 (0.87 
to 1.31) 
54 more per 1000 (from 
100 fewer to 237 more) 
⊕⊕ΟΟ 
LOW 
IMPORTANT
Cosmetic outcome (excellent or good) nBCC patient: PDT vs surgical excision (2 years) assessed by investigator 
1 randomised 
trials 
very 
serious1 
no serious 
inconsistency 
no serious 
indirectness 
serious3 none 24/50 
(48%) 
34% RR 1.41 (0.86 
to 2.31) 
139 more per 1000 (from 
48 fewer to 445 more) 
⊕ΟΟΟ 
VERY LOW 
IMPORTANT
Cosmetic outcome (excellent or good) nBCC patient: PDT vs surgical excision (2 years) assessed by patient 
1 randomised 
trials 
very 
serious1 
no serious 
inconsistency 
no serious 
indirectness 
very serious3 none 28/50 
(56%) 
57.5% RR 0.97 (0.69 
to 1.38) 
17 fewer per 1000 (from 
178 fewer to 218 more) 
⊕ΟΟΟ 
VERY LOW 
IMPORTANT
Cosmetic outcome (excellent or good) nBCC patient: PDT vs surgical excision (5 years) assessed by investigator 
1 randomised 
trials 
very 
serious1 
no serious 
inconsistency 
no serious 
indirectness 
serious3 none 27/50 
(54%) 
40.4% RR 1.34 (0.87 
to 2.06) 
137 more per 1000 (from 
53 fewer to 428 more) 
⊕ΟΟΟ 
VERY LOW 
IMPORTANT
Treatment tolerability - low or manageable pain PDT vs Surgical excision 
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1 randomised 
trials 
serious1 no serious 
inconsistency 
no serious 
indirectness 
serious3 none 27/50 
(54%) 
29.8% RR 1.81 (1.09 
to 3.01) 
241 more per 1000 (from 
27 more to 599 more) 
⊕⊕ΟΟ 
LOW 
IMPORTANT
Treatment tolerability - low or manageable pain PDT vs Surgical excision (during treatment) (Better indicated by lower values) 
1 randomised 
trials 
serious1 no serious 
inconsistency 
no serious 
indirectness 
no serious 
imprecision 
none 15 11 - MD 3.57 higher (1.7 to 
5.44 higher) 
⊕⊕⊕Ο 
MODERATE
IMPORTANT
Treatment tolerability - low or manageable pain PDT vs Surgical excision (immediately after treatment) (Better indicated by lower values) 
1 randomised 
trials 
serious1 no serious 
inconsistency 
no serious 
indirectness 
no serious 
imprecision 
none 15 11 - MD 3.57 higher (1.7 to 
5.44 higher) 
⊕⊕⊕Ο 
MODERATE
IMPORTANT
Treatment tolerability - low or manageable pain PDT vs Surgical excision (3 hours after treatment) (Better indicated by lower values) 
1 randomised 
trials 
serious1 no serious 
inconsistency 
no serious 
indirectness 
very serious3 none 15 11 - MD 1.06 higher (0.41 
lower to 2.53 higher) 
⊕ΟΟΟ 
VERY LOW 
IMPORTANT
Treatment tolerability - low or manageable pain PDT vs Surgical excision (6 hours after treatment) (Better indicated by lower values) 
1 randomised 
trials 
serious1 no serious 
inconsistency 
no serious 
indirectness 
very serious3 none 15 11 - MD 0.66 lower (2.3 lower 
to 0.98 higher) 
⊕ΟΟΟ 
VERY LOW 
IMPORTANT
Treatment tolerability - low or manageable pain PDT vs Surgical excision (24 hours after treatment) (Better indicated by lower values) 
1 randomised 
trials 
serious1 no serious 
inconsistency 
no serious 
indirectness 
very serious3 none 15 11 - MD 0.4 lower (1.7 lower 
to 0.9 higher) 
⊕ΟΟΟ 
VERY LOW 
IMPORTANT
Treatment tolerability - low or manageable pain PDT vs Surgical excision (48 hours after treatment) (Better indicated by lower values) 
1 randomised 
trials 
serious1 no serious 
inconsistency 
no serious 
indirectness 
serious3 none 15 11 - MD 0.6 lower (1.72 lower 
to 0.52 higher) 
⊕⊕ΟΟ 
LOW 
IMPORTANT
Treatment tolerability - low or manageable pain PDT vs Surgical excision (1 week after treatment) (Better indicated by lower values) 
1 randomised 
trials 
serious1 4 no serious 
indirectness 
4 none 15 11 - not pooled 4 IMPORTANT
1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias 
2 No clinical important difference - between MIDs 
3 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs 
4 Unable to assess inconsistency, imprecision or outcome due to mean/SD of 0 
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PDT vs topicals 
 
Quality assessment 
 
No of patients 
 
Effect 
 
 
Quality 
 
 
Importance 
No of 
studies 
Design 
Risk of 
bias 
Inconsistency Indirectness Imprecision 
Other 
considerations 
PDT Topicals 
Relative 
(95% CI) 
Absolute 
Clearance of treated BCC (3 months initial lesion clearance) patient: PDT vs topicals (imiquimod) 
1 randomised 
trials 
very 
serious1 
no serious 
inconsistency 
no serious 
indirectness 
no serious 
imprecision2 
none 165/202 
(81.7%) 
85.9% RR 0.95 (0.87 
to 1.04) 
43 fewer per 1000 (from 
112 fewer to 34 more) 
⊕⊕ΟΟ 
LOW 
CRITICAL 
Clearance of treated BCC (3 months initial lesion clearance) patient: PDT vs topicals (fluorouracil) 
1 randomised 
trials 
very 
serious1 
no serious 
inconsistency 
no serious 
indirectness 
no serious 
imprecision2 
none 165/202 
(81.7%) 
86.6% RR 0.94 (0.87 
to 1.03) 
52 fewer per 1000 (from 
113 fewer to 26 more) 
⊕⊕ΟΟ 
LOW 
CRITICAL 
Sustained clearance of treated BCC (1 year) patient: PDT vs topicals (imiquimod) 
1 randomised 
trials 
very 
serious1 
no serious 
inconsistency 
no serious 
indirectness 
no serious 
imprecision2 
none 135/165 
(81.8%) 
90% RR 0.91 (0.83 
to 0.99) 
81 fewer per 1000 (from 9 
fewer to 153 fewer) 
⊕⊕ΟΟ 
LOW 
CRITICAL 
Sustained clearance of treated BCC (1 year) patient: PDT vs topicals (fluorouracil) 
1 randomised 
trials 
very 
serious1 
no serious 
inconsistency 
no serious 
indirectness 
no serious 
imprecision2 
none 135/165 
(81.8%) 
88.5% RR 0.92 (0.85 
to 1.01) 
71 fewer per 1000 (from 
133 fewer to 9 more) 
⊕⊕ΟΟ 
LOW 
CRITICAL 
Sustained clearance of treated BCC (3 years) patient: PDT vs topicals (imiquimod) 
1 randomised 
trials 
very 
serious1 
no serious 
inconsistency 
no serious 
indirectness 
serious3 none 116/165 
(70.3%) 
84.1% RR 0.84 (0.74 
to 0.94) 
135 fewer per 1000 (from 
50 fewer to 219 fewer) 
⊕ΟΟΟ 
VERY LOW 
CRITICAL 
Sustained clearance of treated BCC (3 years) patient: PDT vs topicals (fluorouracil) 
1 randomised 
trials 
very 
serious1 
no serious 
inconsistency 
no serious 
indirectness 
no serious 
imprecision2 
none 116/165 
(70.3%) 
79.3% RR 0.89 (0.78 
to 1) 
87 fewer per 1000 (from 
174 fewer to 0 more) 
⊕⊕ΟΟ 
LOW 
CRITICAL 
Severe pain patient: MAL-PDT vs topical (imiquimod) 
1 randomised serious1 no serious no serious very serious3 none 35/202 18.7% RR 0.93 (0.61 13 fewer per 1000 (from ⊕ΟΟΟ CRITICAL 
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 trials  inconsistency indirectness   (17.3%)  to 1.41) 73 fewer to 77 more) VERY LOW  
Severe pain patient: MAL-PDT vs topical (fluorouracil) 
1 randomised 
trials 
serious1 no serious 
inconsistency 
no serious 
indirectness 
serious3 none 35/202 
(17.3%) 
9% RR 1.93 (1.13 
to 3.3) 
84 more per 1000 (from 
12 more to 207 more) 
⊕⊕ΟΟ 
LOW 
CRITICAL 
Cosmetic outcome (excellent or good) patient: PDT vs topicals (imiquimod) 
1 randomised 
trials 
serious1 no serious 
inconsistency 
no serious 
indirectness 
no serious 
imprecision2 
none 116/202 
(57.4%) 
57.1% RR 1.01 (0.85 
to 1.19) 
6 more per 1000 (from 86 
fewer to 108 more) 
⊕⊕⊕Ο 
MODERATE 
IMPORTANT 
Cosmetic outcome (excellent or good) patient: PDT vs topicals (fluorouracil) 
1 randomised 
trials 
serious1 no serious 
inconsistency 
no serious 
indirectness 
no serious 
imprecision2 
none 116/202 
(57.4%) 
55.2% RR 1.04 (0.88 
to 1.24) 
22 more per 1000 (from 
66 fewer to 132 more) 
⊕⊕⊕Ο 
MODERATE 
IMPORTANT 
Other adverse effects (serious and unexpected reactions): PDT vs topicals (imiquimod) 
1 randomised 
trials 
serious1 no serious 
inconsistency 
no serious 
indirectness 
serious3,4 none 0/202 
(0%) 
4.8% RR 0.05 (0 to 
0.84) 
46 fewer per 1000 (from 8 
fewer to 48 fewer) 
⊕⊕ΟΟ 
LOW 
IMPORTANT 
Other adverse effects (serious and unexpected reactions): PDT vs topicals (fluorouracil) 
1 randomised 
trials 
serious1 no serious 
inconsistency 
no serious 
indirectness 
very serious3,4 none 0/202 
(0%) 
2% RR 0.11 (0.01 
to 2.04) 
18 fewer per 1000 (from 
20 fewer to 21 more) 
⊕ΟΟΟ 
VERY LOW 
IMPORTANT 
1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias 
2 No clinical important difference - between MIDs 
3 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs 
4 No events on one arm 
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Combination PDT vs PDT 
 
Quality assessment 
 
No of patients 
 
Effect 
 
 
Quality 
 
 
Importance 
No of 
studies 
Design Risk of bias Inconsistency Indirectness Imprecision 
Other 
considerations 
Combination 
PDT 
PDT 
Relative 
(95% CI) 
Absolute 
Clearance of treated BCC (3 months initial lesion clearance) patient: ALA-PDT + imiquimod vs ALA-PDT 
1 randomised 
trials 
very serious1 no serious 
inconsistency 
no serious 
indirectness 
very 
serious2 
none 18/24 
(75%) 
60% OR 2 (0.42 to 
9.58) 
150 more per 1000 
(from 213 fewer to 335 
more) 
⊕ΟΟΟ 
VERY LOW 
CRITICAL 
Recurrence rate (>1 year) patient: ALA-PDT + imiquimod vs ALA-PDT 
1 randomised 
trials 
no serious 
risk of bias 
no serious 
inconsistency 
no serious 
indirectness 
very 
serious2 
none 1/24 
(4.2%) 
0% RR 1.32 (0.06 
to 29.92) 
- ⊕⊕ΟΟ 
LOW 
CRITICAL 
Clearance of treated BCC (3 months initial lesion clearance) patient: AFXL-MAL-PDT vs MAL-PDT 
1 randomised 
trials 
no serious 
risk of bias 
no serious 
inconsistency 
no serious 
indirectness 
serious2 none 16/16 
(100%) 
87.5% RR 1.14 (0.92 
to 1.41) 
122 more per 1000 
(from 70 fewer to 359 
more) 
⊕⊕⊕Ο 
MODERATE
CRITICAL 
Clearance of treated BCC (3 months initial lesion clearance) lesion: AFL-PDT (Er:YAG) vs MAL-PDT 
1 randomised 
trials 
no serious 
risk of bias 
no serious 
inconsistency 
no serious 
indirectness 
serious2 none 16/21 
(76.2%) 
42.9% RR 1.78 (1.03 
to 3.08) 
335 more per 1000 
(from 13 more to 892 
more) 
⊕⊕⊕Ο 
MODERATE
CRITICAL 
Sustained clearance of treated BCC (1 year) patient: AFXL-MAL-PDT vs MAL-PDT 
1 randomised 
trials 
no serious 
risk of bias 
no serious 
inconsistency 
no serious 
indirectness 
serious2 none 13/16 
(81.3%) 
64.3% RR 1.26 (0.8 
to 1.99) 
167 more per 1000 
(from 129 fewer to 637 
more) 
⊕⊕⊕Ο 
MODERATE
CRITICAL 
Sustained clearance of treated BCC (1 year) lesion: AFL-PDT (Er:YAG) vs MAL-PDT 
1 randomised 
trials 
no serious 
risk of bias 
no serious 
inconsistency 
no serious 
indirectness 
serious2 none 15/16 
(93.8%) 
44.4% RR 2.11 (1.01 
to 4.43) 
493 more per 1000 
(from 4 more to 1000 
⊕⊕⊕Ο 
MODERATE
CRITICAL 
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          more)   
Recurrence rate (1 year) lesion: AFXL-MAL-PDT vs MAL-PDT 
1 randomised 
trials 
no serious 
risk of bias 
no serious 
inconsistency 
no serious 
indirectness 
serious2 none 3/16 
(18.8%) 
43.8% RR 0.43 (0.13 
to 1.37) 
250 fewer per 1000 
(from 381 fewer to 162 
more) 
⊕⊕⊕Ο 
MODERATE
CRITICAL 
Cosmetic outcome (excellent) patient: AFXL-MAL-PDT vs MAL-PDT (3 months) assessed by investigator 
1 randomised 
trials 
no serious 
risk of bias 
no serious 
inconsistency 
no serious 
indirectness 
very 
serious2 
none 11/16 
(68.8%) 
56.3% RR 1.22 (0.71 
to 2.11) 
124 more per 1000 
(from 163 fewer to 625 
more) 
⊕⊕ΟΟ 
LOW 
IMPORTANT
Cosmetic outcome (excellent) patient: AFXL-MAL-PDT vs MAL-PDT (3 months) assessed by patient 
1 randomised 
trials 
no serious 
risk of bias 
no serious 
inconsistency 
no serious 
indirectness 
serious2 none 13/16 
(81.3%) 
50% RR 1.62 (0.94 
to 2.8) 
310 more per 1000 
(from 30 fewer to 900 
more) 
⊕⊕⊕Ο 
MODERATE
IMPORTANT
Cosmetic outcome (excellent) patient: AFXL-MAL-PDT vs MAL-PDT (6 months) assessed by investigator 
1 randomised 
trials 
no serious 
risk of bias 
no serious 
inconsistency 
no serious 
indirectness 
serious2 none 12/16 
(75%) 
37.5% RR 2 (1 to 4) 375 more per 1000 
(from 0 more to 1000 
more) 
⊕⊕⊕Ο 
MODERATE
IMPORTANT
Cosmetic outcome (excellent) patient: AFXL-MAL-PDT vs MAL-PDT (6 months) assessed by patient 
1 randomised 
trials 
no serious 
risk of bias 
no serious 
inconsistency 
no serious 
indirectness 
serious2 none 12/16 
(75%) 
50% RR 1.5 (0.85 
to 2.64) 
250 more per 1000 
(from 75 fewer to 820 
more) 
⊕⊕⊕Ο 
MODERATE
IMPORTANT
Cosmetic outcome (excellent) patient: AFXL-MAL-PDT vs MAL-PDT (9 months) assessed by investigator 
1 randomised 
trials 
no serious 
risk of bias 
no serious 
inconsistency 
no serious 
indirectness 
very 
serious2 
none 8/16 
(50%) 
43.8% RR 1.14 (0.54 
to 2.4) 
61 more per 1000 (from 
201 fewer to 613 more) 
⊕⊕ΟΟ 
LOW 
IMPORTANT
Cosmetic outcome (excellent) patient: AFXL-MAL-PDT vs MAL-PDT (9 months) assessed by patient 
1 randomised 
trials 
no serious 
risk of bias 
no serious 
inconsistency 
no serious 
indirectness 
very 
serious2 
none 10/16 
(62.5%) 
50% RR 1.25 (0.67 
to 2.32) 
125 more per 1000 
(from 165 fewer to 660 
more) 
⊕⊕ΟΟ 
LOW 
IMPORTANT
Cosmetic outcome (excellent) patient: AFXL-MAL-PDT vs MAL-PDT (1 year) assessed by investigator 
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1 randomised 
trials 
no serious 
risk of bias 
no serious 
inconsistency 
no serious 
indirectness 
serious2 none 8/16 
(50%) 
25% RR 2 (0.75 to 
5.33) 
250 more per 1000 
(from 62 fewer to 1000 
more) 
⊕⊕⊕Ο 
MODERATE
IMPORTANT
Cosmetic outcome (excellent) patient: AFXL-MAL-PDT vs MAL-PDT (1 year) assessed by patient 
1 randomised 
trials 
no serious 
risk of bias 
no serious 
inconsistency 
no serious 
indirectness 
very 
serious2 
none 9/16 
(56.3%) 
43.8% RR 1.29 (0.64 
to 2.6) 
127 more per 1000 
(from 158 fewer to 701 
more) 
⊕⊕ΟΟ 
LOW 
IMPORTANT
Cosmetic outcome (excellent) lesion: AFL-PDT (Er:YAG) vs MAL-PDT assessed by investigator 
1 randomised 
trials 
no serious 
risk of bias 
no serious 
inconsistency 
no serious 
indirectness 
very 
serious2 
none 12/21 
(57.1%) 
57.1% RR 1 (0.59 to 
1.69) 
0 fewer per 1000 (from 
234 fewer to 394 more) 
⊕⊕ΟΟ 
LOW 
IMPORTANT
Other adverse effects (hyperpigmentation) patient: AFL-PDT (Er:YAG) vs MAL-PDT 
1 randomised 
trials 
no serious 
risk of bias 
no serious 
inconsistency 
no serious 
indirectness 
very 
serious2 
none 12/18 
(66.7%) 
56.3% RR 1.19 (0.69 
to 2.04) 
107 more per 1000 
(from 175 fewer to 586 
more) 
⊕⊕ΟΟ 
LOW 
IMPORTANT
Other adverse effects (hyperpigmentation) patient: AFXL-MAL-PDT vs MAL-PDT (3 months) 
1 randomised 
trials 
no serious 
risk of bias 
3 no serious 
indirectness 
3 none 0/16 
(0%) 
0% not pooled not pooled  IMPORTANT
Other adverse effects (hyperpigmentation) patient: AFXL-MAL-PDT vs MAL-PDT (6 months) 
1 randomised 
trials 
no serious 
risk of bias 
no serious 
inconsistency 
no serious 
indirectness 
very 
serious2 
none 0/16 
(0%) 
6.3% RR 0.33 (0.01 
to 7.62) 
42 fewer per 1000 (from 
62 fewer to 417 more) 
⊕⊕ΟΟ 
LOW 
IMPORTANT
Other adverse effects (hyperpigmentation) patient: AFXL-MAL-PDT vs MAL-PDT (9 months) 
1 randomised 
trials 
no serious 
risk of bias 
no serious 
inconsistency 
no serious 
indirectness 
very 
serious2 
none 0/16 
(0%) 
6.3% RR 0.33 (0.01 
to 7.62) 
42 fewer per 1000 (from 
62 fewer to 417 more) 
⊕⊕ΟΟ 
LOW 
IMPORTANT
Other adverse effects (hyperpigmentation) patient: AFXL-MAL-PDT vs MAL-PDT (1 year) 
1 randomised 
trials 
no serious 
risk of bias 
no serious 
inconsistency 
no serious 
indirectness 
very 
serious2 
none 0/16 
(0%) 
12.5% RR 0.2 (0.01 
to 3.86) 
100 fewer per 1000 
(from 124 fewer to 357 
more) 
⊕⊕ΟΟ 
LOW 
IMPORTANT
Treatment tolerability - low or manageable pain: AFL-PDT (Er:YAG) vs MAL-PDT 
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1 randomised 
trials 
no serious 
risk of bias 
no serious 
inconsistency 
no serious 
indirectness 
very 
serious2 
none 12/20 
(60%) 
47.4% RR 1.27 (0.7 
to 2.29) 
128 more per 1000 
(from 142 fewer to 611 
more) 
⊕⊕ΟΟ 
LOW 
IMPORTANT
1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias 
2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs 
3 Unable to assess inconsistency, imprecision or outcome due to lack of events in either arm 
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Combination PDT vs surgical excision 
 
Quality assessment 
 
No of patients 
 
Effect 
 
 
Quality 
 
 
Importance
No of 
studies 
Design 
Risk of 
bias 
Inconsistency Indirectness Imprecision 
Other 
considerations 
Combination 
PDT 
Surgical
Relative 
(95% CI) 
Absolute 
Clearance of treated BCC (3 months initial lesion clearance) nodular lesion: Combination PDT vs surgical excision 
1 randomised 
trials 
very 
serious1 
no serious 
inconsistency 
no serious 
indirectness 
no serious 
imprecision2 
none 79/85 
(92.9%) 
97.7% RR 0.95 (0.89 
to 1.02) 
49 fewer per 1000 (from 
107 fewer to 20 more) 
⊕⊕ΟΟ 
LOW 
CRITICAL 
Sustained clearance of treated BCC (1 year) nodular lesion: Combination PDT vs surgical excision 
1 randomised 
trials 
very 
serious1 
no serious 
inconsistency 
no serious 
indirectness 
no serious 
imprecision2 
none 69/79 
(87.3%) 
96.5% RR 0.9 (0.82 
to 0.99) 
97 fewer per 1000 (from 
10 fewer to 174 fewer) 
⊕⊕ΟΟ 
LOW 
CRITICAL 
Sustained clearance of treated BCC (5 years) lesion: Combination PDT vs surgical excision 
1 randomised 
trials 
very 
serious1 
no serious 
inconsistency 
no serious 
indirectness 
serious3 none 42/79 
(53.2%) 
74.4% RR 0.71 (0.56 
to 0.91) 
216 fewer per 1000 
(from 67 fewer to 327 
fewer) 
⊕ΟΟΟ 
VERY 
LOW 
CRITICAL 
Recurrence rate (>1 year <2 years) lesion: Combination PDT vs surgical excision 
1 randomised 
trials 
very 
serious1 
no serious 
inconsistency 
no serious 
indirectness 
serious3,4 none 5/69 
(7.2%) 
0% RR 13.2 (0.74 
to 234.59) 
- ⊕ΟΟΟ 
VERY 
LOW 
CRITICAL 
Recurrence rate (>1 year <5 years) lesion: Combination PDT vs surgical excision 
1 randomised very no serious no serious serious3,4 none 12/69 0% RR 30 (1.81 to - ⊕ΟΟΟ CRITICAL 
 trials serious1 inconsistency indirectness   (17.4%)  497.72)  VERY 
LOW 
 
1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias 
2 No clinical important difference - between MIDs 
3 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs 
4 No events on one arm 
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Fractionated PDT vs PDT 
 
Quality assessment 
 
No of patients 
 
Effect 
 
 
Quality 
 
 
Importance 
No of 
studies 
Design 
Risk of 
bias 
Inconsistency Indirectness Imprecision 
Other 
considerations 
Fractionated 
PDT 
PDT 
Relative 
(95% CI) 
Absolute 
Sustained clearance of treated BCC (1 year) lesion: ALA-PDT (2-fold) vs ALA-PDT (single) 
1 randomised 
trials 
serious1 no serious 
inconsistency 
no serious 
indirectness 
no serious 
imprecision2 
none 252/262 
(96.2%) 
86.8% RR 1.11 (1.05 
to 1.17) 
95 more per 1000 (from 
43 more to 148 more) 
⊕⊕⊕Ο 
MODERATE 
CRITICAL 
Sustained clearance of treated BCC (5 years) lesion: PDT (2-fold) vs PDT (single) 
1 randomised 
trials 
serious1 no serious 
inconsistency 
no serious 
indirectness 
serious3 none 376/471 
(79.8%) 
60.2% RR 1.33 (1.19 
to 1.47) 
199 more per 1000 
(from 114 more to 283 
more) 
⊕⊕ΟΟ 
LOW 
CRITICAL 
Severe pain (leading to break in treatment/use of local analgesia) patient: ALA-PDT (2-fold) vs ALA-PDT (single) 
1 randomised 
trials 
serious1 no serious 
inconsistency 
no serious 
indirectness 
no serious 
imprecision 
none 9/55 
(16.4%) 
3% RR 5.45 (1.54 
to 19.32) 
133 more per 1000 
(from 16 more to 550 
more) 
⊕⊕⊕Ο 
MODERATE 
CRITICAL 
1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias 
2 No clinical important difference - between MIDs 
3 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed 
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Table S5 Non-pain adverse events (AE) 
Study 
(Comparator) 
Assessment of adverse effects* Notes on adverse effects other than pain* 
Foley 20091 
(Placebo-PDT) 
A study nurse (blinded) monitored 
adverse events during treatment 
sessions and at follow-up.  Severity, 
duration and need for additional 
therapy was recorded.  
MAL-PDT, total adverse effects 74% (erythema 21%, crusting 8%, bleeding 6%) 
Placebo-PDT, total adverse effects 46% ( erythema 6%, crusting 5%) 
All local adverse events were of mild to moderate intensity resolving within 1 day except 
bleeding, crusting, and erythema persisting for 3, 5 and 32 days respectively. 
Basset-Seguin 
20082 
(Cryosurgery) 
Enquiry of adverse effects occurred at 
each follow-up visit, up to 3 months 
after the final treatment.  Effect 
severity and causal relationship was 
recorded.  Additionally a safety 
follow-up telephone call was 
performed fortnightly after 
treatments. 
MAL-PDT total adverse effects 73% (crusting 35%, erythema 30%) Severity mild 80%, 
moderate 13%, severe 5% 
Cryo total adverse effects 79% (crusting 47%, erythema 21%, blisters 21%) Severity mild 
73%, moderate 25%, severe 1% 
All local adverse events were transient, resolving within 5 days with the exception of 
crusting, erythema and itching with both treatments and suppuration in the cryosurgery 
group. 
Wang 2001
3
 
(Cryosurgery) 
Visual analogue scale (VAS) 
completed by patient in first week 
after treatment. 
Significantly shorter healing time after ALA-PDT as compared with cryosurgery. 
Leakage, oedema and erythema assessed at 1 week. 
MAL-PDT: Leakage (none 57%, mild 9%, moderate 9%, severe 0%), oedema (none 61%, 
mild 11%, moderate 0%, severe 0%), erythema (none 5%, mild 45%, moderate 20%, severe 
0%). 
Cryosurgery: Leakage (none 16%, mild 18%, moderate 27%, severe 11%), oedema (none 
25%, mild 36%, moderate 9%, severe 2%), erythema (none 2%, mild 41%, moderate 27%, 
severe 4%) 
Berroeta 20074 
(Surgery) 
 Not stated 
Mosterd 20085 
Roozeboom 
20136 
(Surgery) 
Adverse events of the two treatment 
modalities were documented at 
review 
Secondary wound infection was observed once after ALA–PDT treatment 
Rhodes 2004
7
 
Rhodes 20078 
(Surgery) 
Skin reactions from MAL application 
and illumination documented with 
adverse event severity, duration, and 
any additional therapy. 
Adverse effects more common with MAL-PDT (52%) than surgery (29%) p = 0.03 
PDT: erythema:14%, skin infection 0%, crusting 4%, itching 2% 
Surgery: erythema:2%, skin infection 6%, crusting 0%, itching 0% 
Local adverse events were of mild to moderate intensity, and all resolved in < 1 day. 
Szeimies 20089 
(Surgery) 
Adverse events (AEs), were recorded 
at each visit together with their 
severity, duration and need for 
additional therapy.  
MAL-PDT adverse events: photosensitivity (31%), milia (2%). 
Surgery adverse events: wound infection (5.2%), erythema (3.1%), wound dehiscence 
(2.1%).  
Arits 2013
10
 
Roozeboom 
201611 
Jansen 2017
12
 
(IMQ or  FU) 
Local adverse reactions (redness, 
swelling, erosion, crusts, vesicles, 
squamae, and itching) were reported 
on a scale of 1–4.  Serious adverse 
reactions were also recorded by the 
treating physician. 
Suspected unexpected serious adverse reactions: MAL-PDT 0%, IMQ 4.8%, FU 2.1%. 
Symptoms during treatment (moderate/severe) and signs (moderate/severe) during 
treatment weeks: 
MAL-PDT treatment weeks (1,2) 
Redness (37%), swelling (3%, 4%), erosions (5%, 8%), crusts (8%, 11%), blistering (6%, 8%), 
squamae (6%, 5%), itching (9%, 12%) . 
IMQ treatment weeks (1,2,3,4,5,6) 
Redness (36%, 52%, 56%, 56%, 56%, 55%, 49%), swelling (14%, 21%, 19%, 20%, 19%, 19%), 
erosions (5%, 16%, 24%, 30%, 28%, 26%), crusts (5%, 23%, 29%, 34%, 34%, 36%), blistering 
(5%, 14%, 11%, 14%, 12%, 13%), squamae (1%, 3%, 4%, 5%, 8%, 7%), itching (19%, 28%, 
27%, 30%, 31%, 28%,), tingling (4%, 4%, 3%, 4%, 4%, 4%). 
FU treatment weeks (1,2,3,4) 
Redness (31%, 51%, 61%, 59%), swelling (3%, 7%, 16%, 19%), erosions (5%, 17%, 31%, 
31%), crusts (3%, 11%, 20%, 27%), blistering (4%, 10%, 18%, 17%), squamae (2%, 6%, 6%, 
7%), itching (10%, 21%, 33%, 35%). 
Smucler 200813 
(Er:YAG-laser, 
Er:YAG-laser/PDT) 
None described  Not described 
Haak 201514 
(CO2-AFL/PDT) 
At the clinical assessments, adverse 
reactions were graded on a 4-point 
scale of severity. 
Per patient other adverse effects (hyperpigmentation) at 3 months AFL-MAL-PDT 0% vs 
MAL-PDT 0% 
Per patient other adverse effects (hyperpigmentation) at 6 months AFL-MAL-PDT 0% vs 
MAL-PDT 6% : RR 0.33: 95%CI 0.01–7.62, p = 0.49 
Per patient other adverse effects (hyperpigmentation) at 9 months AFL-MAL-PDT 0% vs 
MAL-PDT 6% : RR 0.33: 95%CI 0.01–7.62, p = 0.49 
Per patient other adverse effects (hyperpigmentation) at1 year AFL-MAL-PDT 0% vs MAL-
PDT 13% : RR 0.20: 95%CI 0.01–3.86, p = 0.29 
Choi 201615 
(Er:YAG-AFL/PDT) 
 Although no patient discontinued the study because of adverse events, all patients in both 
groups experienced some adverse events, most commonly crusting. 
No patients discontinued the study because of adverse events but all patients reported ≥ 1 
adverse events. Frequently reported adverse events (AFL-PDT/MAL-PDT) 
Crusting (94%/88%), erythema (94%/88%), hyperpigmentation (67%/56%), itching 
(22%/18%), scale (17%/13%), blistering (17%/13%), oozing (11%/6%), bleeding (11%/6%) 
Osiecka 201216 
(PDT/IMQ) 
None described Most patients during and after PDT complained of erythema and oedema that persisted 
for several days. Patients complained of increasing symptoms such as itching, large 
oedema, and strong irritation of skin, with erosions, after each application of IMQ. 
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Study 
(Comparator) 
Assessment of adverse effects* Notes on adverse effects other than pain* 
De Haas 200617 
De Vijlder 201218 
(Fractionated 
PDT) 
  
Kessels 201719 
(Fractionated 
ALA-PDT) 
 Erythema %: MAL-PDT vs ALA-PDT 2-fold: absent/mild 50.7% vs 16.3%; moderate/severe 
38.4% vs 73.8%, p < 0.001; not available 11% vs 10%. 
Swelling %: MAL-PDT vs ALA-PDT 2-fold: absent/mild 83.6% vs 78.8%; moderate/severe 
6.8% vs 11.3%, p = 0.406; not available 9.6% vs 10%. 
Wounds %: MAL-PDT vs ALA-PDT 2-fold: absent/mild 82.2% vs 70%; moderate/severe 5.5% 
vs 20%, p = 0.014; not available 12.3% vs 10%. 
Crusts %: MAL-PDT vs ALA-PDT 2-fold: absent/mild 82.2% vs 71.3%; moderate/severe 8.2% 
vs 18.8%, p = 0.062; not available 9.6% vs 10%. 
Vesicles %: MAL-PDT vs ALA-PDT 2-fold: absent/mild 83.6% vs 67.5%; moderate/severe 
6.8% vs 22.5%, p = 0.011; not available 9.6% vs 10%. 
Scaling %: MAL-PDT vs ALA-PDT 2-fold: absent/mild 80.8% vs 71.3%; moderate/severe 
9.6% vs 17.5%, p = 0.160; not available 9.6% vs 11.3%. 
Pruritus %: MAL-PDT vs ALA-PDT 2-fold: absent/mild 72.6% vs 70%; moderate/severe 
17.8% vs 20%, p = 0.835; not available 9.6% vs 10%. 
*These are adverse events other than pain, therefore excluding reference to pain, burning sensation, stinging, tingling etc. 
MAL, methyl aminolaevulinate; ALA, 5-aminolaevulinic acid; PDT, photodynamic therapy; CI, confidence interval; RR, risk ratio; LA, local anaesthetic; 
VAS, visual analogue scale; FU, 5-fluorouracil; IMQ, imiquimod; AFL, Ablative Fractional Laser; Er:YAG, Erbium-doped Yttrium-Aluminium-Garnet; 
CO2-AFL, carbon dioxide Ablative Fractional Laser. 
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Appendix S1 Forest plots 
Basal Cell Carcinoma (BCC) (n) - nodular, (s) - superficial 
NB: If the outcome being measured is positive i.e. clearance the intervention will 
appear on the righthand axis of the forest plots. If negative i.e. severe pain, the 
intervention will appear on the left hand axis of the forest plots. 
PDT vs. Placebo-PDT 
Clearance of treated nBCC (3 months initial lesion clearance) lesion: MAL-PDT vs 
placebo PDT (vehicle cream) 
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Severe pain (leading to break in treatment/use of local analgesia) nBCC patient: MAL-
PDT vs placebo-PDT (vehicle cream)  
(NB. The risk ratio cannot be estimated when there are no events on either arm) 
 
Cosmetic outcome (excellent or good) nBCC lesion: MAL-PDT vs placebo-PDT (vehicle 
cream) 
 
Treatment tolerability - low or manageable pain, nBCC patient: MAL-PDT vs placebo-
PDT (vehicle cream) 
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PDT vs. Cryosurgery 
Clearance of treated sBCC (3 months initial lesion clearance) patient: MAL-PDT vs 
cryosurgery 
 
 
Sustained clearance of treated sBCC (1 year) patient: MAL-PDT vs cryosurgery 
 
 
Sustained clearance of treated sBCC (5 years) patient: MAL-PDT vs cryosurgery 
 
Recurrence rate (1 year) sBCC patient: ALA-PDT vs cryosurgery 
 
NB: Change in scale 
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Recurrence rate (1 year) nBCC patient: ALA-PDT vs cryosurgery 
 
NB: Change in scale 
Recurrence rate (>1 year <2 years) sBCC patient: MAL-PDT vs cryosurgery 
 
 
Recurrence rate (>1 year <3 years) sBCC patient: MAL-PDT vs cryosurgery 
 
 
Recurrence rate (>1 year <4 years) sBCC patient: MAL-PDT vs cryosurgery 
 
Recurrence rate (>1 year <5 years) sBCC patient: MAL-PDT vs cryosurgery 
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Severe pain (leading to break in treatment/use of local analgesia) BCC patient: PDT vs 
cryosurgery 
 
NB: Change in scale 
Cosmetic outcome (excellent) sBCC patient: MAL-PDT vs cryosurgery (3 months) 
assessed by investigator 
 
 
Cosmetic outcome (excellent) sBCC patient: MAL-PDT vs cryosurgery (3 months) 
assessed by patient 
 
Cosmetic outcome (excellent) BCC patient: PDT vs cryosurgery (1 year) assessed by 
investigator 
 
NB: Wang (2001) treated one lesion per patient (ALA-PDT); Basset-Seguin (2008) treated all lesions for each 
patient (MAL-PDT) 
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Cosmetic outcome (excellent) sBCC patient: MAL-PDT vs cryosurgery (1 year) assessed 
by patient 
 
 
Cosmetic outcome (excellent) sBCC patient: MAL-PDT vs cryosurgery (2 years) assessed 
by investigator 
 
 
Cosmetic outcome (excellent) sBCC patient: MAL-PDT vs cryosurgery (2 years) assessed 
by patient 
 
Cosmetic outcome (excellent) sBCC patient: MAL-PDT vs cryosurgery (3 years) assessed 
by investigator 
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Cosmetic outcome (excellent) sBCC patient: MAL-PDT vs cryosurgery (4 years) assessed 
by investigator 
 
 
Cosmetic outcome (excellent) sBCC patient: MAL-PDT vs cryosurgery (5 years) assessed 
by investigator 
 
 
Treatment tolerability - low or manageable pain sBCC: MAL-PDT vs cryosurgery 
 
NB: Change in scale 
PDT vs. Surgical excision 
Clearance of treated sBCC (3 months initial lesion clearance) lesion: MAL-PDT vs 
surgical excision 
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Clearance of treated nBCC (3 months initial lesion clearance) lesion: PDT vs surgical 
excision 
 
 
Sustained clearance of treated sBCC (1 year) lesion: MAL-PDT vs surgical excision 
 
 
Sustained clearance of treated nBCC (1 year) lesion: PDT vs surgical excision 
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Sustained clearance of treated nBCC (5 years) patient: MAL-PDT vs surgical excision 
 
 
Sustained clearance of treated NMSC (5 years) lesion: PDT vs surgical excision 
NB: Change in scale 
Recurrence rate (>1 year <2 years) nBCC lesion: PDT vs surgical excision 
 
NB: Change in scale 
Recurrence rate (>1 year <5 years) nBCC lesion: PDT vs surgical excision 
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Cosmetic outcome (excellent or good) nBCC patient: MAL-PDT vs surgical excision (3 
months) assessed by investigator 
 
NB: Change in scale 
Cosmetic outcome (excellent or good) nBCC patient: MAL-PDT vs surgical excision (3 
months) assessed by patient 
 
 
Cosmetic outcome (excellent or good) sBCC patient: MAL-PDT vs surgical excision (1 
year) assessed by investigator 
 
 
Cosmetic outcome (excellent or good) nBCC patient: MAL-PDT vs surgical excision (1 
year) assessed by investigator 
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Cosmetic outcome (excellent or good) nBCC patient: MAL-PDT vs surgical excision (1 
year) assessed by patient 
 
Cosmetic outcome (excellent or good) nBCC patient: MAL-PDT vs surgical excision (2 
years) assessed by investigator 
 
 
Cosmetic outcome (excellent or good) nBCC patient: MAL-PDT vs surgical excision (2 
years) assessed by patient 
 
 
Cosmetic outcome (excellent or good) nBCC patient: MAL-PDT vs surgical excision (5 
years) assessed by investigator 
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Treatment tolerability - low or manageable pain nBCC: MAL-PDT vs surgical excision 
 
Treatment tolerability - low or manageable pain PDT vs Surgical excision (during 
treatment) 
 
NB: Change in scale 
Treatment tolerability - low or manageable pain PDT vs Surgical excision (immediately 
after treatment) 
 
 
 Treatment tolerability - low or manageable pain PDT vs Surgical excision (3 hours after 
treatment) 
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Treatment tolerability - low or manageable pain PDT vs Surgical excision (6 hours after 
treatment) 
 
 
Treatment tolerability - low or manageable pain PDT vs Surgical excision (24 hours 
after treatment) 
 
Treatment tolerability - low or manageable pain PDT vs Surgical excision (48 hours 
after treatment) 
 
 
Treatment tolerability - low or manageable pain PDT vs Surgical excision (1 week after 
treatment) 
 
(NB. The risk ratio cannot be estimated when the mean is zero) 
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PDT vs. Topicals 
Clearance of treated sBCC (3 months initial lesion clearance) patient: MAL-PDT vs 
imiquimod 
 
NB: Change in scale 
Clearance of treated sBCC (3 months initial lesion clearance) patient: MAL-PDT vs 
fluorouracil 
 
 
Sustained clearance of treated sBCC (1 year) patient: MAL-PDT vs imiquimod 
 
 
Sustained clearance of treated sBCC (1 year) patient: MAL-PDT vs fluorouracil 
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Sustained clearance of treated sBCC (3 years) patient: MAL-PDT vs imiquimod 
 
 
Sustained clearance of treated sBCC (3 years) patient: MAL-PDT vs fluorouracil 
 
Sustained clearance of treated sBCC (5 years) patient: MAL-PDT vs imiquimod 
 
Sustained clearance of treated sBCC (5 years) patient: MAL-PDT vs fluorouracil 
 
Severe pain sBCC patient: MAL-PDT vs imiquimod 
 
NB: (1) Change in scale 
(2) Pain is measured at treatment and then each week for 2 weeks for PDT and each week for 4 weeks for 
fluorouracil and for 6 weeks for imiquimod. The events record is the cumulative number of patients that 
reported pain at each timepoint. This will almost certainly count patients who have experienced severe pain 
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on multiple occasions multiple times.  Though a patient who had severe pain for all 6 weeks is more severely 
affected than a patient who only experienced severe pain for a single week. 
Severe pain (leading to break in treatment/use of local analgesia) sBCC patient: MAL-
PDT vs fluorouracil 
 
NB: Pain is measured at treatment and then each week for 2 weeks for PDT and each week for 4 weeks for 
fluorouracil and for 6 weeks for imiquimod. The events record is the cumulative number of patients that 
reported pain at each timepoint. This will almost certainly count patients who have experienced severe pain 
on multiple occasions multiple times. Though a patient who had severe pain for all 6 weeks is more severely 
affected than a patient who only experienced severe pain for a single week 
Cosmetic outcome (excellent or good) sBCC patient: MAL-PDT vs imiquimod 
 
NB: Change in scale 
Cosmetic outcome (excellent or good) sBCC patient: MAL-PDT vs fluorouracil 
 
 
Other adverse effects (serious and unexpected reactions): PDT vs imiquimod 
 
NB: Change in scale 
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Other adverse effects (serious and unexpected reactions): PDT vs fluorouracil 
 
Combination PDT vs. PDT 
Clearance of treated BCC (3 months initial lesion clearance) patient: ALA-PDT + 
imiquimod vs ALA-PDT 
 
NB: Sub-type of BCC not stated. 
Recurrence rate (>1 year) BCC patient: ALA-PDT + imiquimod vs ALA-PDT 
 
NB: Sub-type of BCC not stated. 
Clearance of treated nBCC (3 months initial lesion clearance) patient: Ablative 
fractional laser-MAL-PDT vs MAL-PDT 
 
NB: Change in scale 
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Clearance of treated nBCC (3 months initial lesion clearance) lesion: Er:YAG ablative 
fractional laser-PDT vs MAL-PDT 
 
 
Clearance of treated nBCC (3 months initial lesion clearance) patient: Er:YAG-laser-PDT 
vs Er:YAG laser 
 
Clearance of treated nBCC (3 months initial lesion clearance) patient: Er:YAG-laser-PDT 
vs MAL-PDT 
 
Sustained clearance of treated nBCC (1 year) patient: Ablative fractional laser -MAL-
PDT vs MAL-PDT 
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Sustained clearance of treated nBCC (1 year) lesion: Er:YAG ablative fractional laser-
PDT vs MAL-PDT 
 
 
Sustained clearance of treated nBCC (1 year) lesion: Er:YAG-laser-PDT vs Er:YAG laser 
 
 
Sustained clearance of treated nBCC (1 year) lesion: patient: Er:YAG-laser-PDT vs MAL-
PDT 
 
Recurrence rate (1 year) nBCC lesion: Ablative fractional laser -MAL-PDT vs MAL-PDT 
 
NB: Change of scale 
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Cosmetic outcome (excellent) nBCC patient: Ablative fractional laser-MAL-PDT vs MAL-
PDT (3 months) assessed by investigator 
 
NB: Change in scale 
Cosmetic outcome (excellent) nBCC patient: Ablative fractional laser-MAL-PDT vs MAL-
PDT (3 months) assessed by patient 
 
 
Cosmetic outcome (aesthetic result) nBCC patient: Er:YAG-laser-PDT vs Er:YAG (3 
months) assessed by evaluator 
 
Cosmetic outcome (aesthetic result) nBCC patient: Er:YAG-laser-PDT vs MAL-PDT (3 
months) assessed by evaluator 
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Cosmetic outcome (excellent) nBCC patient: Ablative fractional laser-MAL-PDT vs MAL-
PDT (6 months) assessed by investigator 
 
 
Cosmetic outcome (excellent) nBCC patient: Ablative fractional laser-MAL-PDT vs MAL-
PDT (6 months) assessed by patient 
 
 
Cosmetic outcome (aesthetic result) nBCC patient: Er:YAG-laser-PDT vs Er:YAG (6 
months) assessed by evaluator 
 
Cosmetic outcome (aesthetic result) nBCC patient: Er:YAG-laser-PDT vs MAL-PDT (6 
months) assessed by evaluator 
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Cosmetic outcome (excellent) nBCC patient: Ablative fractional laser-MAL-PDT vs MAL-
PDT (9 months) assessed by investigator 
 
Cosmetic outcome (excellent) nBCC patient: Ablative fractional laser-MAL-PDT vs MAL-
PDT (9 months) assessed by patient 
 
 
Cosmetic outcome (aesthetic result) nBCC patient: Er:YAG-laser-PDT vs Er:YAG (9 
months) assessed by evaluator 
 
Cosmetic outcome (aesthetic result) nBCC patient: Er:YAG-laser-PDT vs MAL-PDT (9 
months) assessed by evaluator 
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Cosmetic outcome (excellent) nBCC patient: Ablative fractional laser-MAL-PDT vs MAL-
PDT (1 year) assessed by investigator 
 
 
Cosmetic outcome (excellent) nBCC patient: Ablative fractional laser-MAL-PDT vs MAL-
PDT (1 year) assessed by patient 
 
 
Cosmetic outcome (excellent) nBCC lesion: Er:YAG ablative fractional laser-PDT vs 
MALPDT assessed by investigator 
 
 
Treatment tolerability - low or manageable pain: Er:YAG ablative fractional laser-PDT 
vs MAL-PDT 
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Other adverse effects (hyperpigmentation) patient: Er:YAG ablative fractional laser-
PDT vs MAL-PDT 
 
NB: Change in scale 
Other adverse effects (hyperpigmentation) nBCC patient: Ablative fractional laser-
MAL-PDT vs MAL-PDT (3 months) 
 
NB: (1) Change in scale, and  
(2) the risk ratio cannot be estimated when there are no events on either arm. 
Other adverse effects (hyperpigmentation) nBCC patient: Ablative fractional laser-
MAL-PDT vs MAL-PDT (6 months) 
 
 
Other adverse effects (hyperpigmentation) nBCC patient: Ablative fractional laser-
MAL-PDT vs MAL-PDT (9 months) 
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Other adverse effects (hyperpigmentation) nBCC patient: Ablative fractional laser-
MAL-PDT vs MAL-PDT (1 year) 
 
Combination PDT vs. surgical excision 
Clearance of treated NMSC (3 months initial lesion clearance) nodular lesion: ALA-PDT 
+ debulking vs surgical excision 
NB: Change in scale 
 
Sustained clearance of treated NMSC (1 year) nodular lesion: ALA-PDT + debulking vs 
surgical excision 
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Sustained clearance of treated NMSC (5 years) lesion: ALA-PDT + debulking vs surgical 
excision 
NB: Change in scale 
 
Recurrence rate (>1 year <2 years) lesion: ALA-PDT + debulking vs surgical excision 
NB: Change in scale 
 
Recurrence rate (>1 year <5 years) lesion: ALA-PDT + debulking vs surgical excision 
 
Fractionated PDT vs. PDT 
Clearance of treated sBCC (3 months initial lesion clearance) patient: Fractionated ALA-
PDT vs MAL-PDT 
 
NB: Change in scale 
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Sustained clearance of treated sBCC (1 year) patient: Fractionated ALA-PDT vs 
MAL-PDT 
 
 
Sustained clearance of treated sBCC (1 year) lesion: Fractionated ALA-PDT vs ALA-PDT 
NB: Change in scale 
 
Sustained clearance of treated sBCC (5 years) lesion: Fractionated PDT vs ALA-PDT 
 
 
Cosmetic outcome (good or excellent) sBCC patient: Fractionated ALA-PDT vs MAL-PDT 
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Severe pain (leading to break in treatment/use of local analgesia) sBCC patient: 
Fractionated ALA-PDT vs ALA-PDT 
NB: Change in scale 
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